

**ShareHope Medicine Co., Ltd.**  
**Parent Company Only Financial Report**  
**and Independent Auditors' Report**  
**2025 and 2024**

**Address: 19th Floor, No. 168 Jingguo Road, Taoyuan District, Taoyuan**  
**Tel.: (03)3469595**

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

## Table of Contents

Item	Page No.
I. Cover page	1
II. Table of Contents	2
III. Independent Auditors' Report	3
IV. Balance Sheet	4
V. Statement of Comprehensive Income	5
VI. Statement of Changes in Equity	6
VII. Statement of Cash Flow	7
VIII. Notes to the Parent Company Only Financial Reports	
(I) Company History	8
(II) Date and Procedure of the Approval of the Financial Statements	8
(III) Application of Newly Issued and Amended Standards and Interpretations	8-10
(IV) Summary of Major Accounting Policies	10-25
(V) Major Sources of Uncertainty in Major Accounting Judgments, Estimates and Assumptions	26-27
(VI) Explanation of Significant Accounting Items	27-67
(VII) Transactions of Related Parties	67-77
(VIII) Pledged Assets	77
(IX) Material Contingent Liabilities and Unrecognized Contractual Commitments	77
(X) Material Losses from Disasters	77
(XI) Material Subsequent Events	77
(XII) Others	78
(XIII) Items Disclosed in Notes	
1. Information on major transactions	79-84
2. Information on reinvestment	84
3. Information on investments in mainland China	84
(XIV) Department Information	85
IX. Schedule of Significant Accounting Items	86-93

## **Independent Auditors' Report**

Submitted to the Board of Directors of ShareHope Medicine Co., Ltd. and subsidiaries for review

### **Audit opinion**

We have audited the Balance Sheet of ShareHope Medicine Co., Ltd. on December 31, 2025 and 2024, and the Statement of Comprehensive Income, Statement of Changes in Equity, Cash Flow Statement and Notes to Parent Company Only Financial Statements (including the Summary of Major Accounting Policies) from January 1 to December 31, 2025 and 2024.

In our opinion, the Parent Company Only Financial Statements referred to above have been prepared, in all material respects, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and are sufficient to adequately express the financial position of ShareHope Medicine Co., Ltd. on December 31, 2025 and 2024 as well as its financial performance and cash flows from January 1 to December 31, 2025 and 2024.

### **Foundation of the Audit Opinion**

The independent auditor performed the audit in compliance with the rules governing the certification of financial statements by entrusted independent auditors and the auditing standards. His responsibilities specified in these standards will be further explained in the section about independent auditors' responsibilities in auditing the Parent Company Only Financial Statements. The personnel subject to independence standards in the accounting firm, to which the said independent auditor is affiliated, have maintained independent from ShareHope Medicine Co., Ltd. in accordance with the CPA Professional and Ethical Guidelines, and have fulfilled other obligations under the Guidelines. We believe that we have obtained sufficient and appropriate audit evidence as the basis for expressing our audit opinion.

### **Key Audit Matters**

Key audit matters refer to matters of greatest importance to the audit of the Parent Company Only Financial Statements of ShareHope Medicine Co., Ltd. for 2025 based on our professional judgment. Such items have been considered in the course of auditing the Parent Company Only Financial Statements and forming the audit opinions, and the independent auditor determines that the following key audit item shall be communicated in the audit report:

#### **Revenue recognition**

For the accounting policies for revenue recognition and related disclosure information, please refer to Note 4(14), Note 6(22), and Note 7(3) of the Parent Company Only Financial Statements.

Explanation on key audit items:

The operating revenue of ShareHope Medicine Co., Ltd. is a matter of concern to users of the financial statements and the competent authorities, and the Group's main sales customers are related parties of its medical system, whose operating revenue has a significant impact on the Parent Company Only Financial Statements. Accordingly, revenue recognition is among the important items to be evaluated by the independent auditor in the audit of the Parent Company Only Financial Statements of ShareHope Medicine Co., Ltd.

Corresponding audit procedures:

The main audit procedures adopted by the independent auditor for the key audit items mentioned above include:

- Based on the understanding of the sales-related internal control procedures of ShareHope Medicine Co., Ltd., establish internal control audit procedures in response to the risks generated thereof, in order to identify and evaluate the effectiveness of the internal control over sales transactions made by ShareHope Medicine Co., Ltd. with its related parties.
- Obtain sales revenue details from the management, confirm the completeness of the details, select adequate samples from the revenue details of main sales transactions with related parties, and review relevant vouchers and verify the delivery of goods and receipt of payments, so as to confirm whether the revenues are recognized after relevant obligations are fulfilled as well as the authenticity of revenue recognition.
- Inspect whether there are major discounts or returns of sales revenue subsequent to the sales transactions and evaluate the authenticity of the sales revenue.
- Send a letter of inquiry to relevant parties and confirm whether the recorded revenue is consistent with the transaction amount or has been adjusted appropriately.

### **Responsibilities of the management and governing body for the Parent Company Only Financial Report**

The responsibility of the management is to prepare fairly presented Parent Company Only Financial Statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and to maintain necessary internal control over the preparation of the Parent Company Only Financial Statements, so as to ensure no occurrence of material false statements due to fraud or error in the Parent Company Only Financial Statements.

The responsibility of the management in the preparation of the Parent Company Only Financial Statements also includes the evaluation of the ability of ShareHope Medicine Co., Ltd. to continue business, the disclosure of related items, and the adoption of the accounting basis for continuation of the business, unless the management intends to liquidate ShareHope Medicine Co., Ltd. or close business, or there is no practical alternative to liquidation or close of the business.

The governing body (including the Audit Committee) of ShareHope Medicine Co., Ltd. is responsible for supervising the financial reporting process.

## **Responsibilities of the independent auditor for auditing the Parent Company Only Financial Statements**

The purpose of the independent auditor's audit of the Parent Company Only Financial Statements is to obtain reasonable assurance as to whether there are material false statements due to fraud or error in the Parent Company Only Financial Statements, and to issue an audit report. Reasonable assurance refers to the high degree of certainty. Nevertheless, there is no guarantee that the material false statements in the Parent Company Only Financial Statements will necessarily be detected merely based on the audit work conducted in compliance with the auditing standards. False statements may result from frauds or errors. False statements of several amounts or total amounts are considered material if they can reasonably be expected to affect the economic decisions made by users of the Parent Company Only Financial Statements.

The independent auditor performs professional judgment and professional skepticism when conducting an audit in accordance with the auditing standards. The independent auditor also undertakes the following tasks:

1. Identify and evaluate the risk of material false statements due to frauds or errors in the Parent Company Only Financial Statements, formulate and implement appropriate countermeasures for the risk evaluated, and obtain sufficient and appropriate audit evidence as the basis for audit opinions. Since fraud may involve collusion, forgery, intentional omission, false statements, or overstepping internal control, the risk of the failure to detect material false statements due to frauds is higher than that due to errors.
2. Obtain necessary understanding of the internal control essential to the audit, so as to formulate the appropriate audit procedures for the current situation, for all that the purpose is not to give opinions on the effectiveness of the internal control of ShareHope Medicine Co., Ltd.
3. Evaluate the appropriateness of the accounting policies adopted by the management, as well as the reasonability of the accounting estimates and related disclosures made by them.
4. Draw conclusions on the appropriateness of the management's adoption of the accounting basis for continuation of the business, as well as whether there are significant uncertainties in events or situations that may give rise to material doubts about the ability of ShareHope Medicine Co., Ltd. to continue its business, based on the audit evidences obtained. If the independent auditor believes that there are significant uncertainties in such events or situations, he shall remind users of the Consolidated Financial Statements to pay attention to the disclosures about the Parent Company Only Financial Statements, or revise the audit opinions when such disclosures are inappropriate. The independent auditor's conclusions are based on the audit evidences obtained up to the date of the audit report. However, ShareHope Medicine Co., Ltd. may lose the ability to continue the business due to future events or situations.
5. Evaluate the overall statements, structure, and contents of the Parent Company Only Financial Statements (including relevant notes), and whether relevant transactions and events are fairly presented in the Parent Company Only Financial Statements.

6. Obtain sufficient and appropriate audit evidence for the financial information of the investees applying the equity method to give opinions on the Parent Company Only Financial Statements. The independent auditor is responsible for guiding, supervising, and executing the audit work, and for issuing audit opinions on the ShareHope Medicine Co., Ltd.

The items on which the independent auditor has communicated with the governing body include the planned scope and time of the audit work, as well as major audit findings (including significant deficiencies in internal control identified in the course of the audit).

The independent auditor has also provided the governing body with the statement that the personnel subject to independence standards in the accounting firm, to which the independent auditor is affiliated, have complied with the CPA professional and ethical guidelines regarding independence, and has communicated with the governing body on all relationships and other items that may be considered to affect the independence of independent auditors (including relevant protective measures).

We decided on the key matters to be audited in the Parent Company Only Financial Statements of ShareHope Medicine Co., Ltd. for 2025 based on the matters on which we communicated with the governing body. The independent auditor has stated such items in the Independent Auditors' Report, unless some specific items are prohibited from disclosure according to laws and regulations, or the independent auditor decides not to communicate some items in the Independent Auditors' Report under extremely rare circumstances where it can be reasonably expected that the negative impact of such communication will outweigh the public interest it brings.

KPMG Taiwan

Astor Kou

CPAs:

Sinney Kuo

Number of documents approved and certified by the securities regulatory

Tai-Tsai-Zheng-(6)-Zi-0930106739  
Jin-Kuan-Zheng-Shen-Zi-1040003949

March 13, 2026

**ShareHope Medicine Co., Ltd.**

**Balance sheet**

**December 31, 2025 and 2024**

**Unit: NT\$ thousand**

Assets		2025.12.31		2024.12.31		Liabilities and equity		2025.12.31		2024.12.31	
		Amount	%	Amount	%			Amount	%	Amount	%
<b>Current assets:</b>						<b>Current liabilities:</b>					
1100	Cash and cash equivalents (Note 6(1))	\$ 948,146	18	984,469	18	2150	Notes payable	\$ 1,214	-	5,600	-
1110	Financial assets at fair value through profit or loss - current (Note 6(2))	10,769	-	10,610	-	2170	Accounts payable	515,740	10	498,660	9
1120	Current financial assets at fair value through other comprehensive income (Note 6(3))	87,264	2	-	-	2180	Accounts payable - related parties (Note 7)	1,017	-	768	-
1150	Notes receivable (Note 6(4) and (22))	787	-	547	-	2200	Other payables (Note 6(17))	98,104	2	134,966	3
1170	Net accounts receivable (Note 6(4), (6) and (22))	66,929	2	67,429	1	2220	Other accounts payable - related parties (Note 7)	837	-	1,614	-
1180	Accounts receivable - related parties, net (Note 6(4), (6), (22), and 7)	1,060,532	20	946,760	17	2230	Income tax liabilities for the period	17,726	-	23,475	-
1200	Other accounts receivable (Note 6(5))	2,409	-	2,810	-	2280	Lease liabilities - current (Note 6(15))	41,092	1	45,295	1
1210	Other accounts receivable - related parties (Note 6(5) and Note 7)	2,779	-	241,225	5	2322	Long-term loans due in one year or one operating cycle (Note 6(14) and 8)	59,714	1	98,769	2
130X	Inventories (Note 6(7))	27,241	1	32,907	1	2399	Other current liabilities	24,533	1	19,569	-
1410	Prepayments (Note 7)	1,285	-	1,730	-		<b>Total current liabilities</b>	<u>759,977</u>	<u>15</u>	<u>828,716</u>	<u>15</u>
1470	Other current assets	384	-	3,908	-		<b>Non-current liabilities:</b>				
	<b>Total current assets</b>	<u>2,208,525</u>	<u>43</u>	<u>2,292,395</u>	<u>42</u>	2540	Long-term borrowings (Note 6(14) and 8)	776,286	15	761,436	14
	<b>Non-current assets:</b>					2570	Deferred income tax liabilities (Note 6(19))	-	-	17,013	1
1510	Financial assets at fair value through profit or loss - non-current (Note 6(2))	24,210	-	27,853	-	2580	Lease liabilities - non-current (Note 6(15))	211,770	4	250,982	5
1517	Financial assets at fair value through other comprehensive income - non-current (Note 6(3))	275,773	5	580,750	11	2640	Net defined benefit liabilities - non-current (Note 6(18))	7,868	-	7,267	-
1536	Financial assets at amortized cost - non-current (Note 8)	30,000	1	30,000	1	2645	Deposits received (Note 7)	8,286	-	15,859	-
1550	Equity method investments (Note 6(8))	512,765	10	542,708	10		<b>Total non-current liabilities</b>	<u>1,004,210</u>	<u>19</u>	<u>1,052,557</u>	<u>20</u>
1600	Property, plant and equipment (Note 6(10) and Note 8)	1,363,071	26	1,341,865	25		<b>Total liabilities</b>	<u>1,764,187</u>	<u>34</u>	<u>1,881,273</u>	<u>35</u>
1755	Right-of-use assets (Note 6(11))	239,379	5	283,867	5		<b>Equity (Note 6(9) and (20)):</b>				
1780	Intangible assets (Note 6(12))	8,802	-	4,340	-	3110	Ordinary share capital	1,376,404	26	1,310,861	24
1840	Deferred tax assets (Note 6(19))	46,155	1	7,953	-	3200	Additional paid-in capital	1,150,776	22	1,150,037	21
194D	Net long-term finance lease receivables (Note 6(6) and Note 7)	4,819	-	7,517	-	3310	Legal reserves	249,091	5	229,009	4
1990	Other non-current assets (Note 6(13) and 7)	494,449	9	318,920	6	3350	Undistributed earnings	810,797	16	819,984	15
	<b>Total non-current assets</b>	<u>2,999,423</u>	<u>57</u>	<u>3,145,773</u>	<u>58</u>	3410	Exchange difference from translation of the financial statements of foreign operations	(2,158)	-	(1,338)	-
						3420	Unrealized gains or losses on financial assets at fair value through other comprehensive income	(141,149)	(3)	48,342	1
							<b>Total equity</b>	<u>3,443,761</u>	<u>66</u>	<u>3,556,895</u>	<u>65</u>
							<b>Total liabilities and equity</b>	<u>\$ 5,207,948</u>	<u>100</u>	<u>5,438,168</u>	<u>100</u>
	<b>Total assets</b>	<u>\$ 5,207,948</u>	<u>100</u>	<u>5,438,168</u>	<u>100</u>						

(Please refer to the attached Notes to the Consolidated Financial Statements for details)

Chairman: Hung-Jen Yang

Manager: Ching-Wen Liu

Chief Accounting Officer: Ya-Mei Huang

**ShareHope Medicine Co., Ltd.**  
**Statement of Comprehensive Income**  
**January 1 to December 31, 2025 and 2024**

Unit: NT\$ thousand

	2025		2024	
	Amount	%	Amount	%
4000 <b>Operating revenue (Notes 6(22) and 7)</b>	\$ 2,391,181	100	2,408,310	100
5000 <b>Operating costs (Notes 6(7), (10), (11), (12), (15), (18) and Note 7)</b>	<u>(2,053,376)</u>	<u>(86)</u>	<u>(2,047,004)</u>	<u>(85)</u>
<b>Gross profit</b>	<u>337,805</u>	<u>14</u>	<u>361,306</u>	<u>15</u>
<b>Operating expenses (Note 6(4), (10), (11), (12), (15), (18), (23) and Note 7):</b>				
6100 Marketing expenses	(17,078)	(1)	(16,308)	(1)
6200 Administrative expenses	(153,673)	(6)	(164,984)	(7)
6450 Expected credit impairment (reversal gain) loss	<u>218</u>	<u>-</u>	<u>(3)</u>	<u>-</u>
<b>Total operating expenses</b>	<u>(170,533)</u>	<u>(7)</u>	<u>(181,295)</u>	<u>(8)</u>
6500 Net other income and expenses (Notes 6(24) and 7)	<u>45,109</u>	<u>2</u>	<u>155,922</u>	<u>7</u>
<b>Total other income and expenses</b>	<u>45,109</u>	<u>2</u>	<u>155,922</u>	<u>7</u>
<b>Net operating income</b>	<u>212,381</u>	<u>9</u>	<u>335,933</u>	<u>14</u>
<b>Non-operating income and expenses (Note 6(2), (8), (15) and (25), and Note 7):</b>				
7100 Interest income	7,697	-	6,447	-
7010 Other income	11,472	-	53,134	2
7020 Other gains and losses	(3,750)	-	8,319	-
7050 Finance costs	(27,604)	(1)	(35,441)	(1)
7070 Share of profits and losses of subsidiaries and affiliates recognized by the equity method	<u>(24,431)</u>	<u>(1)</u>	<u>(120,168)</u>	<u>(5)</u>
<b>Total non-operating income and expenses</b>	<u>(36,616)</u>	<u>(2)</u>	<u>(87,709)</u>	<u>(4)</u>
7900 <b>Net income before tax</b>	175,765	7	248,224	10
7950 <b>Income tax expense (Note 6(19))</b>	<u>(34,038)</u>	<u>(1)</u>	<u>(48,127)</u>	<u>(2)</u>
<b>Net income for the period</b>	141,727	6	200,097	8
8300 <b>Other comprehensive income (Note 6(18), (19) and (20)):</b>				
8310 <b>Items not reclassified to profit or loss</b>				
8311 Remeasurement amount of defined benefit plans	(370)	-	(49)	-
8316 Unrealized valuation profits and losses on equity instrument investments at fair value through other comprehensive income	(241,114)	(10)	(68,390)	(3)
8330 Share of other comprehensive income of subsidiaries and affiliates recognized by the equity method	(1,349)	-	(10,888)	-
8349 Less: income taxes related to non-reclassified items	<u>(53,596)</u>	<u>(2)</u>	<u>(3,235)</u>	<u>-</u>
<b>Total items not reclassified to profit or loss</b>	<u>(189,237)</u>	<u>(8)</u>	<u>(76,092)</u>	<u>(3)</u>
8360 <b>Items that may be reclassified to profit or loss subsequently</b>				
8361 Exchange difference from translation of the financial statements of foreign operations	(152)	-	953	-
8380 Share of other comprehensive income of subsidiaries recognized by the equity method	(698)	-	407	-
8399 Less: income taxes related to items that may be reclassified	<u>(30)</u>	<u>-</u>	<u>191</u>	<u>-</u>
<b>Total items that may be reclassified to profit or loss subsequently</b>	<u>(820)</u>	<u>-</u>	<u>1,169</u>	<u>-</u>
8300 <b>Other comprehensive income for this period (net of tax)</b>	<u>(190,057)</u>	<u>(8)</u>	<u>(74,923)</u>	<u>(3)</u>
8500 <b>Total comprehensive income for this period</b>	<u>\$ (48,330)</u>	<u>(2)</u>	<u>125,174</u>	<u>5</u>
<b>Earnings per share (NT\$) (Note 6(21))</b>				
9750 <b>Basic earnings per share</b>	<u>\$ 1.03</u>		<u>1.45</u>	
9850 <b>Diluted earnings per share</b>	<u>\$ 1.03</u>		<u>1.45</u>	

(Please refer to the attached Notes to the Consolidated Financial Statements for details)

Chairman: Hung-Jen Yang

Manager: Ching-Wen Liu

Chief Accounting Officer: Ya-Mei Huang

**ShareHope Medicine Co., Ltd.**  
**Statement of Changes in Equity**  
**January 1 to December 31, 2025 and 2024**

Unit: NT\$ thousand

	Ordinary share capital	Additional paid- in capital	Legal reserves	Undistributed earnings	Exchange difference from translation of the financial statements of foreign operations	Unrealized gains or losses on financial assets at fair value through other comprehensive income	Total equity
<b>Balance on January 1, 2024</b>	\$ 1,260,443	1,155,834	216,895	732,111	(2,507)	125,160	3,487,936
Net income for the period	-	-	-	200,097	-	-	200,097
Other comprehensive income for the period	-	-	-	726	1,169	(76,818)	(74,923)
Total comprehensive income for this period	-	-	-	200,823	1,169	(76,818)	125,174
Allocation and distribution of earnings:							
Appropriation of legal reserve	-	-	12,114	(12,114)	-	-	-
Common share cash dividend	-	-	-	(50,418)	-	-	(50,418)
Ordinary share stock dividend	50,418	-	-	(50,418)	-	-	-
Changes in ownership interests in subsidiaries	-	(5,797)	-	-	-	-	(5,797)
<b>Balance on December 31, 2024</b>	1,310,861	1,150,037	229,009	819,984	(1,338)	48,342	3,556,895
Net income for the period	-	-	-	141,727	-	-	141,727
Other comprehensive income for the period	-	-	-	254	(820)	(189,491)	(190,057)
Total comprehensive income for this period	-	-	-	141,981	(820)	(189,491)	(48,330)
Allocation and distribution of earnings:							
Appropriation of legal reserve	-	-	20,082	(20,082)	-	-	-
Common share cash dividend	-	-	-	(65,543)	-	-	(65,543)
Ordinary share stock dividend	65,543	-	-	(65,543)	-	-	-
Changes in ownership interests in subsidiaries	-	739	-	-	-	-	739
<b>Balance at December 31, 2025</b>	\$ 1,376,404	1,150,776	249,091	810,797	(2,158)	(141,149)	3,443,761

(Please refer to the attached Notes to the Consolidated Financial Statements for details)

Chairman: Hung-Jen Yang

Manager: Ching-Wen Liu

Chief Accounting Officer: Ya-Mei Huang

**ShareHope Medicine Co., Ltd.**

**Cash Flow Statement**

**January 1 to December 31, 2025 and 2024**

**Unit: NT\$ thousand**

	<b>2025</b>	<b>2024</b>
<b>Cash flows from (used in) operating activities:</b>		
<b>Net income before tax for the period</b>	\$ 175,765	248,224
<b>Items adjusted:</b>		
Income and expense items		
depreciation expense	143,399	148,076
Amortization expenses	5,217	2,595
Expected credit impairment (reversal gain) loss	(218)	3
Net loss (profit) on financial assets and liabilities measured at fair value through profit or loss	3,712	(8,316)
Interest expenses	27,604	35,441
Interest income	(7,697)	(6,447)
Dividend income	(2,652)	(46,287)
Share of losses of subsidiaries and affiliates recognized by the equity method	24,431	120,168
Gains on disposal and retirement of properties, plants and equipment	(7,286)	(118,256)
Total income and expense items	186,510	126,977
Changes in assets/liabilities related to operating activities:		
Notes receivable (including related parties)	(240)	156
Accounts receivable (including related parties)	(109,147)	113,972
Lease payments receivable (including related parties)	267	9,625
Other receivables (including related parties)	(887)	(514)
Inventories	5,666	9,070
Prepayments (including related parties)	2,430	5,392
Other current assets	3,523	(738)
contract liability	(31,219)	134
Notes payable	(4,386)	(1,800)
Accounts payable (including related parties)	17,163	(139,713)
Other payables (including related parties)	(32,738)	12,686
Other current liabilities	(37)	2,121
Net defined benefit liabilities	231	(1,011)
Total net changes in assets and liabilities related to operating activities	(149,374)	9,380
Cash inflow from operation	212,901	384,581
Interests received	7,697	6,447
Interests paid	(27,731)	(35,479)
Income taxes paid	(55,465)	(74,246)
<b>Net cash inflow from operating activities</b>	<b>137,402</b>	<b>281,303</b>

**(Please refer to the attached Notes to the Consolidated Financial Statements for details)**

**Chairman:**

**Hung-Jen Yang**

**Manager:**

**Ching-Wen Liu**

**Chief Accounting Officer:**

**Ya-Mei Huang**

**ShareHope Medicine Co., Ltd.**  
**Cash Flow Statement (Continued)**  
**January 1 to December 31, 2025 and 2024**

	<b>Unit: NT\$ thousand</b>	
	<b>2025</b>	<b>2024</b>
<b>Cash flows from (used in) investing activities:</b>		
Acquisition of financial assets at fair value through other comprehensive income	\$ (9,614)	(42,510)
Capital returned due to capital reduction in financial assets at fair value through other comprehensive income	13,443	4,040
Acquisition of financial assets at fair value through profit or loss	(228)	-
Acquisition of equity method investments	(20,000)	(45,006)
Disposal of equity method investments	-	893
Acquisition of property, plant and equipment	(114,163)	(42,370)
Disposal of property, plant and equipment	9,954	61,881
Acquisition of intangible assets	(11,480)	(3,179)
Cash inflow from mergers	21,296	-
Loss (gain) on disposal of investment properties	240,000	-
Decrease in other non-current assets	804	933
(Increase) decrease in refundable deposits	(92,092)	9
Dividends received	8,060	44,196
<b>Net cash inflow (outflow) from investing activities</b>	<b>45,980</b>	<b>(21,113)</b>
<b>Cash flows from (used in) financing activities:</b>		
Decrease in short-term loans	(50,000)	(50,000)
Repayment of long-term loans	(54,205)	(95,883)
(Decrease) increase in deposits received	(4,447)	421
Lease principal payment	(45,510)	(47,689)
Distribution of cash dividends	(65,543)	(50,418)
<b>Net cash outflow from financing activities</b>	<b>(219,705)</b>	<b>(243,569)</b>
(Decrease) increase in cash and cash equivalents for the period	(36,323)	16,621
Balance of cash and cash equivalents at the beginning of the period	984,469	967,848
Balance of cash and cash equivalents at the end of the period	<b>\$ 948,146</b>	<b>984,469</b>

**(Please refer to the attached Notes to the Consolidated Financial Statements for details)**

**Chairman:**  
**Hung-Jen Yang**

**Manager:**  
**Ching-Wen Liu**

**Chief Accounting Officer:**  
**Ya-Mei Huang**

**ShareHope Medicine Co., Ltd.**  
**Notes to the Parent Company Only Financial Report**  
**2025 and 2024**

**(Unless otherwise specified, all amounts are in thousands of New Taiwan Dollars)**

**I. Company History**

ShareHope Medicine Co., Ltd. (hereinafter referred to as the Company) was established with the approval of the Ministry of Economic Affairs on October 13, 2003, with its registered address at 19th Floor, No. 168 Jingguo Road, Taoyuan District, Taoyuan City. The Company is mainly engaged in wholesale and retail sales of medicines and hygiene materials, leasing of assets for medical institutions to undertake related medical services, and physical examinations for Taiwanese people and foreign labors, on-site medical support services, hemodialysis business management and ophthalmic medical management in collaboration with medical institutions.

In order to effectively integrate resources and strengthen the organization, a short-form merger with the subsidiary, Medzoneasia Co., Ltd., was approved by the board of directors on December 6, 2024. The Company is the surviving company, and the merger effective date is January 1, 2025.

**II. Date and Procedure of the Approval of the Financial Statements**

The accompanying parent-only financial statements were authorized for issue by the Board of Directors (the "Board") on March 13, 2026.

**III. Application of Newly Issued and Amended Standards and Interpretations**

(I) The impact of adopting newly issued and amended standards and interpretations approved by the Financial Supervisory Commission

The Company initially applied the following amended IFRS Accounting Standards endorsed by the Financial Supervisory Commission from January 1, 2025, which did not have a material impact on the parent company only financial statements.

·Amendments to IAS 21 "Lack of Exchangeability"

·Amendments to IFRS 9 and IFRS 7 "Amendment to the Classification and Measurement of Financial Instruments" regarding the application guidance of Section 4.1 of IFRS 9 and the related disclosure requirements under IFRS 7

(II) Impact of IFRS standards approved by the Financial Supervisory Commission but not yet adopted

The Company has assessed that the initial application of the following amended IFRS Accounting Standards, effective from January 1, 2026, will not have a material impact on the parent company only financial statements.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

- Amendment to "Insurance Contracts" under IFRSs 17 and amendment to IFRSs 17
- Amendments to IFRS 9 and IFRS 7 "Amendment to the Classification and Measurement of Financial Instruments" regarding the application guidance of Section 3.1 and 3.3 of IFRS 9 and the related disclosure requirements under IFRS 7.
- IFRS Annual Improvements
- Amendments to IFRS 9 and IFRS 7 "Contracts Involving Natural Power Sources"

(III) Newly issued and amended standards and interpretations that have not yet been approved by the Financial Supervisory Commission

The standards and interpretations that have been issued and amended by the International Accounting Standards Board but have not yet been approved by the Financial Supervisory Commission and may be relevant to the Company are as follows:

<b>New or amended standards</b>	<b>Major amendment contents</b>	<b>Effective date of standards released by the Board</b>
IFRS 18 "Presentation and Disclosure in Financial Statements"	<p>The new standard introduces three categories of income and expenses, two subtotals of income statement, and a single note on management performance measures. These three amendments and enhanced guidance on how to disaggregate information in financial statements lay the foundation for providing users with better and more consistent information and will affect all companies.</p> <ul style="list-style-type: none"> <li>·More structured income statement: Under existing standards, companies use different formats to present their operating results, making it difficult for investors to compare the financial performance of different companies. The new standard adopts a more structured income statement, introduces a newly defined subtotal of "operating income," and stipulates that all income and expenses are classified into three new different categories based on the company's main operating activities.</li> <li>·Management performance measures (MPMs): The new standard introduces the definition of MPMs and requires companies to disclose,</li> </ul>	<p>January 1, 2027</p> <p>Note: On September 25, 2025, the FSC issued a press release announcing that Taiwan would adopt IFRS No. 18 for the 2028 accounting year. If companies have the need for early adoption, they may do so subject to approval from the FSC.</p>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

in a single note to the financial statements, descriptions of why each measurement is able to provide useful information, how it is calculated, and how these indicators are reconciled with the amounts recognized in accordance with the IFRSs.

- More detailed information: The new standard includes guidance on how companies strengthen the grouping of information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes.

The Company is continuously evaluating the impact of above-mentioned standards and interpretations on its financial position and operating results, and the relevant impact will be disclosed when the evaluation is completed.

The Company expects that the following unapproved newly issued and amended standards will not have a significant impact on the Parent Company Only Financial Statements.

- Amendment to "Sales or Investment of Assets between Investors and Their Affiliates or Joint Ventures" under IFRSs 10 and IAS 28
- IFRS 19 "Subsidiaries without Public Accountability: Disclosures" and the Amendments to IFRS 19
- Amendments to IAS 21 "Translation to a Hyperinflationary Presentation Currency"

#### **IV. Summary of Major Accounting Policies**

The major accounting policies adopted in the Parent Company Only Financial Statements, which have been consistently applied to all periods stated in the Parent Company Only Financial Statements, are summarized as follows:

(I) Compliance statement

The Parent Company Only Financial Statements is prepared in accordance with the Regulations Governing the Preparation of Financial Statements by Securities Issuers.

(II) Preparation basis

1. Measurement basis

The Parent Company Only Financial Statements is prepared on the basis of historical cost, except for the following important items in the balance sheet:

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

- (1) Financial assets at fair value through profit or loss based on fair value measurement;
- (2) Financial assets at fair value through other comprehensive income based on fair value measurement; and
- (3) Net defined benefit liabilities which are measured by deducting the present value of defined benefit obligations from the fair value of pension fund assets.

2. Functional currency and presentation currency

The Company takes the currencies dominant in the primary economic environment in which it operates as its functional currencies. The Parent Company Only Financial Statements is presented in New Taiwan dollars, one of the functional currencies of the Company. All financial information expressed in New Taiwan Dollars is presented in NT\$ thousand.

(III) Foreign currency

1. Foreign currency transactions

Foreign currencies are translated into functional currencies at the exchange rate on the transaction date through foreign currency transactions. At the end of each subsequent reporting period (hereinafter referred to as the reporting date), foreign currency monetary items are translated into functional currencies at the exchange rate on that day.

Foreign currency non-monetary items measured at fair value are translated into functional currencies at the exchange rate on the date of fair value measurement, while foreign currency non-monetary items measured at historical cost are translated at the exchange rate on the transaction date. Foreign currency exchange differences arising from translation are normally recognized in profit or loss, except for equity instruments measured at fair value through other comprehensive income, which are recognized in other comprehensive income.

2. Foreign operations

Assets and liabilities of foreign operations are translated into New Taiwan dollars at the exchange rate at the reporting date, and income and expenses are translated into New Taiwan dollars at the average exchange rate of the current period. The exchange differences generated thereof are recognized in other comprehensive income.

When the disposal of a foreign operation results in loss of control, joint control, or significant impact, the cumulative exchange differences related to the foreign operation shall be reclassified into profit or loss in full. Upon partial disposal of a subsidiary with foreign operations, the related cumulative translation differences shall be reattributed to non-controlling interests on a pro-rata basis. Upon partial disposal of investments in affiliates or

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

joint ventures with foreign operations, the related cumulative translation differences shall be reclassified to profit or loss on a pro-rata basis.

If there is no settlement plan for the monetary receivables or payables of a foreign operation and they are impossible to settle in the foreseeable future, foreign exchange gains and losses arising therefrom shall be regarded as part of the net investment in the foreign operation and recognized in other comprehensive income.

**(IV) Classification criteria for distinguishing current and non-current assets and liabilities**

Assets that meet any of the following conditions are classified as current assets, while any assets other than current assets are classified as non-current assets:

1. The asset is expected to be realized in the normal operating cycle of an enterprise, or is intended for selling or consumption;
2. The asset is held primarily for trading;
3. The asset is expected to be realized within 12 months after the reporting period; or
4. The asset is cash or cash equivalent (as defined in IAS No. 7), unless the asset is subject to restrictions due to asset exchange or liability repayment in at least 12 months after the reporting period.

Liabilities that meet any of the following conditions are classified as current liabilities, while any liabilities other than current liabilities are classified as non-current liabilities:

1. The liability is expected to be settled in the normal operating cycle of an enterprise;
2. The liability is held primarily for trading;
3. The liability is due to be repaid within 12 months after the reporting period; or
4. At the end of the reporting period, the liability does not have the right to defer prepayment for at least twelve months after the reporting period.

**(V) Cash and cash equivalents**

Cash includes cash on hand, cheques, and demand deposits. A cash equivalent refers to a short-term and highly liquid investment that can be converted into a fixed amount of cash at any time with minimal risk of value fluctuation. Time deposits that meet the aforementioned definition and are held for short-term cash commitments rather than investment or other purposes are presented in cash equivalents.

**(VI) Financial instruments**

Accounts receivable are initially recognized when incurred. All other financial assets and liabilities are initially recognized when the Company becomes a party to the contractual terms of the instruments. Financial assets or financial liabilities not at fair value through profit or loss are initially measured at fair value plus transaction costs directly attributable to the

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

acquisition or issuance.

1. Financial assets

For the purchase or sale of financial assets in compliance with customary transactions, the Company shall consistently adopt the trade date or settlement date accounting for all purchases and sales of financial assets classified in the same manner.

Financial assets upon initial recognition are classified as investments in equity instruments at fair value through other comprehensive income or financial assets at fair value through profit or loss.

The Company shall reclassify all affected financial assets from the first day of the next reporting period only if it changes its operating model for financial asset management.

(1) Financial assets at fair value through other comprehensive income

At initial recognition, the Company may make an irrevocable election to present the subsequent changes in the fair value of investments in equity instruments not held for trading in other comprehensive income. The aforementioned election is made on an instrument-by-instrument basis.

Investments in equity instruments are subsequently measured at fair value. Dividend income (unless it clearly represents a recovery of part of the cost of an investment) is recognized in profit or loss. The remaining net profits or losses are recognized in other comprehensive income and are not reclassified to profit or loss.

Dividend income from equity investments is recognized on the date on which the Company is entitled to receive the dividend (usually the ex-dividend date).

(2) Financial assets at fair value through profit or loss

Financial assets that do not belong to the aforementioned financial assets at fair value through other comprehensive income are measured at fair value through profit or loss. At initial recognition, in order to eliminate or significantly reduce accounting mismatch, the Company shall irrevocably designate financial assets that meet the criteria to be measured at amortized cost or at fair value through other comprehensive income as financial assets measured at fair value through profit or loss.

Such assets are subsequently measured at fair value, and their net profits or losses (including any dividends and interest income) are recognized in profit or loss.

(3) Impairment of financial assets

The Company shall recognize expected credit losses on financial assets measured at amortized cost (including cash and equivalents, notes and accounts receivable (including related parties), other receivables, finance lease receivables, and deposits) in loss

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

allowances.

The loss allowances of the following financial assets are measured at 12-month expected credit losses, while those of other financial assets are measured at lifetime expected credit losses.

The credit risk of bank deposits (i.e., the risk of default over the expected life of the financial instruments) has not significantly increased since initial recognition.

The loss allowances for notes and accounts receivable (including related parties) and finance lease receivables are measured at lifetime expected credit losses.

Lifetime expected credit losses refer to expected credit losses resulting from all possible default events over the expected life of the financial instrument.

12-month expected credit losses refer to expected credit losses resulting from financial instrument default events that are possible within 12 months after the reporting date (or a shorter period, if the expected lifetime of the financial instrument is shorter than 12 months).

The longest period for measuring expected credit losses is the longest contract period during which the Company will be exposed to credit risk.

In case of determining whether the credit risk has increased significantly since initial recognition, the Company shall consider reasonable and verifiable information (obtainable without excessive cost or investment), including qualitative and quantitative information, as well as analysis based on the past experience, credit evaluation, and forward-looking information of the Company.

If a contract payment is overdue beyond the agreed payment terms, the Company shall assume that there are signs of credit risk on the financial asset.

If a contract payment is more than 120 days overdue, the Company shall assume that there is a significant increase in the credit risk on the financial asset.

If a contract payment is more than 180 days overdue, the Company shall consider the financial asset to be in default.

Expected credit losses are the probability-weighted estimates of the expected lifetime credit losses of financial instruments. Credit losses, which are measured at the present value of all cash shortfalls, are the difference between the cash flows that the Company can receive under the contract and the cash flows that the Company expects to receive. Expected credit losses are discounted at the effective interest rate of financial assets.

The Company shall evaluate whether the financial assets measured at amortized cost

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

are credit-impaired at each reporting date. A financial asset is credit-impaired when one or more events that have a detrimental impact on the estimated future cash flows of that financial asset have occurred. Evidences of credit impairment of financial assets include observable information about the following situations:

- Significant financial difficulties of the issuer.
- Default, such as more than 180 days delayed or overdue; or
- Disappearance of an active market for that financial asset due to financial difficulties.

When the Company cannot reasonably expect the recovery of a financial asset in whole or in part, it shall directly reduce the total carrying amount of the financial asset. For corporate accounts, the Company shall analyze the timing and amount of write-offs individually based on whether it is reasonably expected to be recoverable, and expect that the written-off amount will not be significantly reversed. However, written-off financial assets are still enforceable to comply with the Company's procedures for recovering overdue amounts.

(4) Derecognition of financial assets

The Company shall derecognize a financial asset when it has terminated its contractual rights to the cash flows from the asset, or has transferred the financial asset and has transferred substantially all the risks and rewards of ownership of the asset to other enterprises, or has neither transferred nor retained substantially all the risks and rewards of the ownership and has not retained control over the financial asset.

2. Financial liabilities and equity instruments

(1) Classification of liabilities or equity

Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity based on the substance of the contractual agreements and the definitions of the financial liabilities and equity instruments.

(2) Equity transaction

An equity instrument refers to any contract that evidences a residual interest in the assets of the Combined Company after deducting all of its liabilities. The equity instruments issued by the Company are recognized as the amount obtained after deducting direct issuance costs.

(3) Financial liabilities

Financial liabilities are classified as liabilities either at amortized cost or at fair value through profit or loss. Financial liabilities that are held for trading, or are derivatives or designated at initial recognition are classified as financial liabilities at fair value through

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

profit or loss. Financial liabilities at fair value through profit or loss are measured at fair value, and related net gains and losses, including any interest expense, are recognized in profit or loss.

Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expenses and exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss.

(4) Derecognition of financial liabilities

The Company shall derecognize financial liabilities when contractual obligations are fulfilled, canceled or expired. When the terms of a financial liability are modified and the cash flows of the modified liability are substantially different from that of the original liability, the original financial liability shall be derecognized, and the new financial liability is recognized at fair value based on the modified terms.

On derecognition of a financial liability, the difference between the carrying amount and the total consideration paid or payable is recognized in profit or loss.

(5) Offsetting of financial assets and financial liabilities

A financial asset and a financial liability shall be offset and the net amount presented in the balance sheet only when the Company currently has a legally enforceable right to set off the asset and liability, and intends to settle on a net basis or realize the asset and settle the liability simultaneously.

3. Derivative financial instruments

An embedded derivative is separated from the host contract provided that certain conditions are met and the host contract is not a financial asset.

A derivative is initially recognized and subsequently measured at fair value, and any gain or loss arising from remeasurement is directly recognized in profit or loss.

(VII) Inventory

Inventories are measured at the lower of cost and net realizable value. Cost includes the acquisition and other costs incurred in bringing the inventories to the location and condition in which they are available for use, and is calculated by the weighted average method.

Net realizable value refers to the estimated selling price in the ordinary course of business minus the estimated selling costs.

(VIII) Investments in affiliates

An affiliate is one that the Company has significant influence on its financial and operating policies but does not have control or share joint control over it.

The Company adopts the equity method to account for its interests in affiliates. Under the

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

equity method, the initial acquisition is recognized at cost, with the transaction costs included in the investment costs. The carrying amount of an investee affiliate includes the goodwill identified at original investment, minus any accumulated impairment loss.

The Parent Company Only Financial Statements comprise profits and losses and other comprehensive income of each investee affiliate recognized based on the equity ratio after adjustments consistent with the Company's accounting policies, from the date of significant influence to the date significant influence is lost. In the event of a change in equity of an affiliate that is not in profit or loss or other comprehensive income and does not affect the shareholding ratio of the Company, the Company shall recognize the change in equity of the affiliate attributable to it in additional paid-in capital according to its shareholding ratio.

Unrealized gains and losses arising from transactions between the Company and affiliates shall be recognized in corporate financial statements only within the scope of the equity of investors in affiliates. When the share of loss of an affiliate that shall be recognized by the Company pro rata equals or exceeds its equity in the affiliate, it shall stop recognition of the loss. The additional losses and related liabilities shall be recognized only to the extent that legal obligations and constructive obligations have occurred or payments have been made on behalf of the investee.

(IX) Investments in subsidiaries

When preparing the Parent Company Only Financial Statements, the Company applies the equity method to valuating the investees controlled by it. Under the equity method, the allocated amount of the current profits and losses and other comprehensive income in the Parent Company Only Financial Statements is the same as that of the current profits and losses and other comprehensive income attributable to the owners of the parent company in the financial statements prepared on a consolidated basis, and the owner's equity in the Parent Company Only Financial Statements is the same as the equity attributable to the owners of the parent company in the financial statements prepared on a consolidated basis.

Changes in the ownership interests of the Company in subsidiaries that do not lead to loss of control shall be accounted for as equity transactions with the owners.

(X) Property, plant and equipment

1. Recognition and measurement

Items of property, plant and equipment are measured at cost minus accumulated depreciation and any accumulated impairment.

Gains or losses on disposal of property, plant and equipment shall be recognized in profit or loss.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

2. Subsequent costs

Subsequent expenditures are capitalized only if it is probable that their future economic benefits will flow to the Combined Company.

3. Depreciation

Depreciation is calculated by deducting residual value from the asset cost, and recognized in profit or loss over the estimated useful life by the straight-line method.

Land shall not be depreciated.

The estimated useful lives for the current and comparative periods are as follows:

(1) Machinery and equipment	1~8 years
(2) Office equipment	2~10 years
(3) Leasehold improvements	3~10 years
(4) Other equipment	2~5 years
(5) Leased assets	5~8 years
(6) Houses and buildings	28~30 years

The Company shall review the depreciation method, useful life, and residual value at each reporting day, and make appropriate adjustments when necessary.

(XI) Lease

The Company shall assess whether a contract is or contains a lease at the date the contract is entered into. A contract is or contains a lease if the contract transfers control over the use of identified assets for a period of time in exchange for consideration.

1. Lessee

The Company shall recognize the right-of-use assets and the lease liabilities at the commencement date of a lease. The right-of-use assets are initially measured at cost, which includes the original measurement amount of the lease liabilities.

The right-of-use assets are subsequently depreciated by the straight-line method from the commencement date of a lease to the maturity date of the useful life or the lease term of the right-of-use assets, whichever is earlier. In addition, the Company shall assess whether the right-of-use assets are impaired on a regular basis and handle any impairment losses incurred, and adjust the right-of-use assets in conjunction with the remeasurement of the lease liabilities.

Lease liabilities are initially measured at the present value of the lease payments that have not been paid at the commencement date of a lease. If the interest rate implicit in the lease is easy to determine, the interest rate shall be the discount rate; if it is not easy to determine, it shall be the incremental borrowing rate of the Combined Company. In general,

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

the Company adopts its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liabilities include:

- (1) Fixed payments (including in-substance fixed payments);
- (2) Variable lease payments that are dependent on an index or a rate and are measured using the index or rate at the lease commencement date.

Interest is subsequently accrued on lease liabilities using the effective interest method and is remeasured under the following circumstances:

- (1) Changes in future lease payments due to changes in the index or rate used to determine lease payments;
- (2) Changes in the evaluation of the purchase option of the underlying assets;
- (3) Changes in the evaluation of the lease term due to changes in the estimation of whether to exercise extension or termination options;
- (4) Changes in the subject matter, scope, or other terms of the leases.

When a lease liability is remeasured due to changes in the index or rate used to determine lease payments as well as changes in the evaluation of purchase, extension, or termination options, the carrying amount of the right-of-use asset shall be adjusted accordingly, and the remaining remeasurement amount shall be recognized in profit or loss when the carrying amount of the right-of-use asset is reduced to zero.

For lease modifications that reduce the scope of a lease, the carrying amount of the right-of-use asset is reduced to reflect partial or full termination of the lease, and the difference between the carrying amount and the remeasurement amount of the lease liability is recognized in profit or loss.

The Company shall present the right-of-use assets and lease liabilities that do not meet the definition of investment property as separate line items in the balance sheet.

For the short-term lease of some buildings and transportation equipment and the lease of low value underlying assets, the Company chooses not to recognize the right-of-use assets and lease liabilities, but recognize the relevant lease payments as expenses during the lease term on a straight-line basis.

## 2. Lessor

Transactions in which the Company is the lessor are classified at the commencement date of the lease based on whether the lease contracts transfer substantially all the risks and rewards attached to the ownership of the underlying asset. If so, the transactions are classified as finance leases, otherwise they are classified as operating leases. When evaluating, the Company shall consider relevant specific indicators including whether the

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

lease term covers the main part of the economic life of the underlying asset.

If the Company is an intermediate lessor in a sublease, the master lease and sublease transactions shall be handled separately, and the sublease transaction shall be classified based on evaluation on the right-of-use asset generated by the master lease. If the master lease is a short-term lease and the recognition exemption applies, the sublease transaction shall be classified as an operating lease.

Assets held under finance leases are presented as finance lease receivables at the net investments in the leases. The original direct costs arising from negotiation and arrangement of an operating lease is included in the net investment in the lease. The net investment in lease is apportioned and recognized as interest income during the lease term in a manner that reflects the fixed rate of return for each period. For operating leases, the Company recognizes the lease payments received as rental income on a straight-line basis during the lease term.

(XII) Intangible assets

1. Recognition and measurement

Goodwill arising from the acquisition of a subsidiary is measured at cost less accumulated impairment.

Intangible assets with a limited useful life acquired by the Company, including management rights, are measured at cost less accumulated amortization.

2. Subsequent expenditures

Subsequent expenditures are capitalized only if the future economic benefits of the relevant specific assets can be increased. All other expenditures are recognized in profit or loss as incurred.

3. Amortization

Except for goodwill, amortization is measured at asset cost less estimated residual value, and is recognized in profit or loss by the straight-line method over the expected useful lives of the intangible assets from the time when they are serviceable.

The estimated useful lives for the current and comparative periods are as follows:

- |                       |          |
|-----------------------|----------|
| (1) Computer software | 3 years  |
| (2) Management right  | 12 years |

The Company shall review the amortization method, useful life, and residual value of intangible assets at each reporting day, and make appropriate adjustments when necessary.

(XIII) Impairment of non-financial assets

The Company shall evaluate whether there are any signs of impairment in the carrying

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

amount of non-financial assets (excluding inventories and deferred income tax assets) at each reporting date. In case of any such sign, the recoverable amount of the assets shall be estimated.

For the purpose of impairment test, a group of assets with the majority of cash inflows independent of the cash inflows of other individual assets or asset groups is designated as the smallest identifiable asset group. Goodwill shall be tested for impairment on an annual and regular basis.

The recoverable amount is the higher of the fair value of an individual asset or cash-generating unit less disposal cost and its value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or cash-generating unit.

If the recoverable amount of an individual asset or cash-generating unit is less than its carrying amount, an impairment loss is recognized.

An impairment loss shall be recognized immediately in profit or loss. In a cash-generating unit, the carrying amount of the amortized goodwill is reduced first; then the carrying amount of other assets is reduced pro rata.

An impairment loss for goodwill is never reversed. Non-financial assets other than goodwill are reversed only if they are not above the carrying amount (net of depreciation or amortization) that they would have been without the recognized impairment loss in previous years.

**(XIV) Revenue recognition**

After the Company identifies performance obligations under a customer contract, the transaction price is allocated to each performance obligation and revenue is recognized when each performance obligation is fulfilled.

Revenue from contracts with customers is measured by the consideration to which they are expected to be entitled for the transfer of goods or services. The Company recognizes the revenue when control of goods or services is transferred to customers and performance obligations are fulfilled.

**1. Sales of goods**

Revenue from product sales mainly comes from sales of products such as medicines and medical materials. The Company recognizes revenue and accounts receivable when the customer has rights to determine the value of and use the products and bears the primary responsibility for re-selling the products and the risk of obsolescence after the products sold arrive at the place designated by the customer or the products are actually delivered to the

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

customer. Prepayments for product sales are recognized as contract liabilities before the transfer of control of the product to the customer.

2. Service income

Service income mainly comes from undertaking physical examinations for Taiwanese people and foreign labors, on-site medical support services, hemodialysis business management, ophthalmic medical management in collaboration with medical institutions, and is recognized as income when performance obligations are fulfilled.

3. Income from medical equipment rental

The Company provides medical equipment leasing services and recognizes related income during the financial reporting period for providing labor services.

Estimates of revenue, costs and completion are modified in case of any change, and the resulting increase or decrease will be reflected in profit or loss during the period when the management becomes aware of the change and makes correction.

Under a fixed price contract, the customer pays a fixed amount according to the agreed schedule. Services provided that exceed the payment are recognized as a contract asset, while a payment that exceeds the services provided is recognized as a contract liability.

(XV) Employees' benefits

1. Defined contribution plans

Contribution obligations to the defined contribution pension plans are recognized as expenses over the period in which the employees render services.

2. Defined benefit plans

The Company's net obligations to the defined benefit plans are calculated by converting the future benefit amount earned from services provided by employees in the current or previous period for each benefit plan into the present value, less the fair value of any plan assets.

The defined benefit obligations are actuarialized annually by a qualified actuary using the projected unit credit method. Assets are recognized to the extent of not exceeding the present value of any economic benefits that would be available in the form of refunds of contributions from the plan or reductions in future contributions to the plan when the calculations may be favorable to the Company. The present value of economic benefits is calculated in consideration of any minimum funding requirement.

The remeasurement amount of net defined benefit liabilities (assets), including actuarial profits, return on plan assets (excluding interest), and any change in the effects of asset caps (excluding interest) are recognized immediately in other comprehensive income

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

and accumulated in retained earnings. The Company determines the net interest expenses on the net defined benefit liabilities based on the net defined benefit liabilities and discount rate determined at the beginning of the annual reporting period. Net interest expenses and other expenses of defined benefit plans are recognized in profit or loss.

Any change in benefits related to prior service costs or reduced benefits or losses arising from program modifications and reduction are immediately recognized in profit or loss. The Company recognizes gains or losses on the settlement of a defined benefit plan upon the occurrence of liquidation.

**3. Short-term employee benefits**

Short-term employee benefit obligations are recognized as expenses when the services are rendered. If the Company has a present legal or constructive obligation to pay for the prior services rendered by employees and the obligation can be reliably estimated, the amount is recognized as a liability.

**(XVI) Income tax**

Income tax includes current and deferred income taxes. Except for items directly recognized in other comprehensive income, current income taxes and deferred income taxes shall be recognized in profit or loss.

Current income taxes include the estimated income taxes payable or tax rebates receivable calculated based on the taxable (losses) income of the current year, as well as any adjustments to the income taxes payable of the previous years. The amount is the best estimate of the expected payables and receivables based on the statutory tax rate or substantively enacted tax rate at the reporting date.

Deferred income taxes are measured and recognized based on the temporary difference between the carrying amount of an asset or liability for financial reporting purposes and its tax base. Deferred income taxes are not recognized for temporary differences arising from:

1. Assets or liabilities that were not originally recognized for a business combination and does not affect accounting profits and taxable income (losses) at the time of the transaction;
2. Temporary differences arising from investments in subsidiaries and affiliates under the circumstances where the Company can control the timing of the reversal of the temporary differences and it is probable that the temporary differences will not be reversed in the foreseeable future; and
3. Taxable temporary differences arising from the original recognition of goodwill.

Unused tax losses and unused income tax credits as well as deductible temporary differences are recognized as deferred income tax assets provided that it is probable that future

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

taxable income will be available for use. And they shall be reassessed at each reporting date, and shall be reduced if it is not probable that related income tax benefit will be realized, or the original reduced amount shall be reversed if it becomes probable that sufficient taxable income will be available.

Deferred income taxes are measured at the tax rate when the expected temporary differences are reversed, based on the statutory tax rate or substantially enacted tax rate at the reporting date.

The Company will offset deferred income tax assets and deferred income tax liabilities only if the following conditions are met simultaneously:

1. Has a legally enforceable right to set off current income tax assets against current income tax liabilities; and
2. Deferred income tax assets and deferred income tax liabilities are related to one of the following taxable entities that are subject to income taxes by the same tax authority;
  - (1) the same taxable entity; or
  - (2) different taxable entities which intend either to settle current income tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred income tax assets or liabilities are expected to be recovered or settled.

**(XVII) Earnings per share**

The Company shall present the basic and diluted earnings per share (EPS) attributable to the ordinary equity holders of the Company. The basic EPS of the Company is calculated by dividing the profits and losses attributable to the ordinary equity holders of the Company by the weighted average number of outstanding ordinary shares in the current period. Diluted EPS is calculated by adjusting the profits and losses attributable to the ordinary equity holders of the Company and the weighted average number of outstanding ordinary shares for the effect of all dilutive potential ordinary shares. The dilutive potential ordinary shares of the Company are distributed to employees as employee remuneration.

**(XVIII) Segment information**

The department information of the Company has been disclosed in the Consolidated Financial Statements, and thus is not disclosed in the Parent Company Only Financial Statements.

**(XIX) Business combination**

The Combined Company measures goodwill at the fair value of the consideration transferred at the acquisition date, including the amount attributable to any non-controlling

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

interests in the acquiree, less the net amount of identifiable assets acquired and liabilities assumed (usually fair value). If the balance after deduction is negative, the Combined Company shall recognize the bargain purchase gain in profit or loss after reassessing whether all assets acquired and liabilities assumed have been correctly identified.

The Company chooses to measure any non-controlling interest at either the fair value at the acquisition date or the ratio of the identifiable net assets to non-controlling interests on a transaction-by-transaction basis.

In a business combination achieved in stages, the Company remeasures its previously held equity interest in the acquiree at the fair value at the acquisition date. Any resulting gain or loss is recognized in profit or loss. For changes in the value of the acquiree's equity that were recognized in other comprehensive income prior to the acquisition date, the Company shall account for them in the same manner as if it had directly disposed of its previously held equity interest; if such amounts would be reclassified to profit or loss upon disposal, they are reclassified to profit or loss.

If the original accounting treatment of a business combination has not been completed before the end of the reporting period in which the combination transaction occurred, for the incomplete accounting items, the Combined Company shall report the provisional amounts which shall be retroactively adjusted during the measurement period, or shall recognize them as additional assets or liabilities to reflect new information obtained during the measurement period regarding the facts and circumstances that already existed at the acquisition date. The measurement period shall not exceed one year from the acquisition date.

Except for those related to the issuance of debt or equity instruments, transaction costs related to business combinations shall be recognized as expenses of the consolidated company as incurred.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

**V. Major Sources of Uncertainty in Major Accounting Judgments, Estimates and Assumptions**

The preparation of the Parent Company Only Financial Statements in conformity with the Regulations and IAS 34 “Interim Financial Reporting” endorsed by the FSC requires management to make judgments, estimates, and assumptions about the future (including climate-related risks and opportunities) that affect the application of the accounting policies and the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.

The management will review estimates and underlying assumptions on an ongoing basis, and changes in accounting estimates are recognized in the period of change and in the future periods affected.

The uncertainty of the following assumptions and estimates carries a significant risk of causing a major adjustment to the carrying amount of assets and liabilities in the next financial year, and has already reflected the impact of the COVID-19 epidemic. The relevant information is as follows:

(I) Valuation of accounts receivable

When there are objective evidences indicating signs of impairment in the assumptions of default rate and expected loss rate of the Company, the Company shall make assumptions and select inputs for impairment assessment in consideration of past experience, current market conditions and forward-looking information. If the actual cash flows in the future are less than expected, a significant impairment loss may be incurred. Please refer to Note 6(4) for details on the provision of accounts receivable impairment.

(II) Valuation of stocks issued by non-TWSE/TPEX listed companies at fair value through other comprehensive income

Given that stocks issued by non-TWSE/TPEX listed companies at fair value through other comprehensive income are measured at fair value, the Company has to rely on external expert evaluation mechanisms to determine the fair value through human judgments, assumptions, and calculations on estimates. Changes in such assumptions due to changes in market and economic conditions may significantly affect the adjustment of fair value recognition. Please refer to Note 6(3) for details on valuation of stocks issued by non-TWSE/TPEX listed companies at fair value through other comprehensive income.

(III) Impairment assessment of investments in subsidiaries

The Company's management assesses impairment based on the future cash flow forecast of the cash-generating units to which the investments in a subsidiary' assets belong. Changes in the economic conditions of the market in which the subsidiary operates or changes in its operating strategies may result in material adjustments to the impairment due to irrecoverable carrying amount of the investments in the subsidiary.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

The accounting policies and disclosures of the Company include the fair value measurement of its financial assets. The Company has established relevant internal control systems for fair value measurement, including significant fair value measurements (including Level 3 fair value measurements) reviewed by accountants, which shall be reported directly to the Chief Financial Officer. Accountants regularly review significant unobservable inputs and adjustments. If the inputs used to measure fair value are based on external third-party information, accountants will evaluate the evidence provided by the third party in support of the inputs to determine that the valuation and its fair value classification are in compliance with IFRSs.

The Company shall adopt market observable inputs to measure its financial assets whenever possible. The fair value hierarchy categorizes the inputs used in the valuation techniques as follows:

- Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: Inputs for assets or liabilities other than quoted prices included within Level 1 that are observable, either directly (i.e., prices) or indirectly (i.e., derived from prices).
- Level 3: Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

In the event of a transfer among the levels of the fair value hierarchy, the Company recognizes the transfer at the reporting date.

Please refer to Note 6(26) below for information about the assumptions adopted in fair value measurement of financial instruments.

**VI. Explanation of Significant Accounting Items**

(I) Cash and cash equivalents

	<b>2025.12.31</b>	<b>2024.12.31</b>
Cash on hand and working capital	\$ 4,076	3,856
Demand deposits	892,521	929,479
Cash equivalents - repurchase bonds	51,549	51,134
	<b>\$ 948,146</b>	<b>984,469</b>

Please refer to Note 6(26) for the disclosure of the interest rate risk and the sensitivity analysis of financial assets and liabilities of the Company.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(II) Financial assets at fair value through profit or loss

	<b>2025.12.31</b>	<b>2024.12.31</b>
<b>Financial assets mandatorily measured at fair value through profit or loss:</b>		
Non-derivative financial assets		
Fund beneficiary certificate	\$ 10,769	10,610
Non-TWSE/TPEX listed stocks	23,983	27,853
Non-TWSE/TPEX listed stocks	227	-
	<b>\$ 34,979</b>	<b>38,463</b>
Current	\$ 10,769	10,610
Non-current	24,210	27,853
	<b>\$ 34,979</b>	<b>38,463</b>

In 2025 and 2024, the Company recognized dividend income of NT\$600 thousand and NT\$600 thousand respectively for the investment in equity instruments mandatorily measured at fair value through profit or loss.

Please refer to Note 6(26) for the amount recognized in profit or loss on fair value re-measurement.

(III) Financial assets at fair value through other comprehensive income

	<b>2025.12.31</b>	<b>2024.12.31</b>
Stocks issued by non-TWSE/TPEX listed companies	\$ 179,232	136,232
Stocks issued by non-listed foreign companies	-	345,774
Foreign listed stocks	87,264	-
Limited partnership equity	96,541	98,744
	<b>\$ 363,037</b>	<b>580,750</b>

1. The investments in equity instruments are held by the Company as long-term strategic investments and not for trading purposes, and thus they have been designated to be measured at fair value through other comprehensive income.
2. The Company did not dispose of any strategic investments in 2025 and 2024. Hence, there was no transfer in equity between accumulated gains and losses. Please refer to Note 6(26) for transfers between fair value hierarchy levels and changes in financial assets.
3. BenQ BM Holding Cayman Corporation was originally shares of a foreign unlisted (unquoted) company. On December 22, 2025, it was officially listed on the Main Board of The Stock Exchange of Hong Kong Limited.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

4. The equity instruments of the limited partnerships invested in by the Company are classified as financial assets at fair value through other comprehensive income. According to the IFRS Q&A issued by the Accounting Research and Development Foundation on June 15, 2023, such investments should be classified as financial assets at fair value through profit or loss. However, the Q&A states that it shall be applied from July 1, 2023. The equity instruments of the limited partnerships invested in by the Company were acquired in 2021, so there is no need for retrospective application.

(IV) Notes and accounts receivable and finance lease receivables - current

	<b>2025.12.31</b>	<b>2024.12.31</b>
Notes receivable	\$ 787	547
Accounts receivable - measured at amortized cost	60,676	67,429
Accounts receivable - related parties - measured at amortized cost	1,054,752	937,376
Accounts receivable - finance lease payments - measured at amortized cost	6,494	-
Accounts receivable - related parties - finance lease payments - measured at amortized cost	6,281	10,436
Less: loss allowances	(1)	(219)
Unrealized interest income	(741)	(833)
	<b>\$ 1,128,248</b>	<b>1,014,736</b>

The Company estimates the expected credit losses on notes and accounts receivable and financial lease receivables (including related parties) by a simplified approach, that is by measuring lifetime expected credit losses. For this purpose, such notes and accounts receivable and financial lease receivables (including related parties) are grouped based on the common credit risk characteristics that represent customers' abilities to pay all amounts due under contractual terms, with forward-looking information incorporated, including overall economic and related industry information.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

The expected credit losses on notes and accounts receivable and finance lease receivables (including related parties) of the Company are analyzed as follows:

	<b>2025.12.31</b>		
	<b>Carrying amount of notes and accounts receivable and finance leases receivable (including related parties)</b>	<b>Weighted average expected credit loss rate</b>	<b>Loss allowance for expected credit losses during lifetime</b>
Not overdue	\$ 1,125,092	0.00%~0.00%	-
Less than 60 days overdue	1,835	0.00%~0.01%	-
61~90 days overdue	697	0.00%~0.02%	-
91~120 days overdue	625	0.00%~0.10%	1
	<b>\$ 1,128,249</b>		<b>1</b>
		<b>2024.12.31</b>	
	<b>Carrying amount of notes and accounts receivable and finance leases receivable (including related parties)</b>	<b>Weighted average expected credit loss rate</b>	<b>Loss allowance for expected credit losses during lifetime</b>
Not overdue	\$ 1,014,866	0.00%~0.02%	219
Less than 60 days overdue	89	0.00%~2.28%	-
	<b>\$ 1,014,955</b>		<b>219</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

The changes in the loss allowances for notes and accounts receivable and finance lease receivables (including related parties) of the Company are analyzed in the table below:

	<b>2025</b>	<b>2024</b>
Beginning balance	\$ 219	216
Recognized impairment losses (gains on reversal)	(218)	3
Ending balance	<b>\$ 1</b>	<b>219</b>

(V) Other receivables

	<b>2025.12.31</b>	<b>2024.12.31</b>
Dividends receivable	\$ -	2,810
Other receivables - related parties	2,779	241,225
Others	2,409	-
Less: loss allowances	-	-
	<b>\$ 5,188</b>	<b>244,035</b>

Please refer to Note 6(26) for information on credit risk.

(VI) Finance lease receivables

The Company subleases machinery and equipment for a period of two to ten years, with an implied interest rate of 5% to 9% under the lease agreements, covering the entire remaining period of the main lease agreement. Therefore, such subleases are classified as finance leases.

The maturity analysis of lease payments is presented in the following table based on the undiscounted lease payments to be received after the reporting date:

	<b>2025.12.31</b>	<b>2024.12.31</b>
Less than one year	\$ 12,775	10,436
1~2 years	2,853	4,518
2~3 years	1,879	1,985
3~4 years	101	1,599
4~5 years	101	-
More than 5 years	262	-
Gross investment in the lease	17,971	18,538
Unearned finance income	(1,118)	(1,418)
Present value of lease payments receivable	<b>\$ 16,853</b>	<b>17,120</b>
	<b>2025.12.31</b>	<b>2024.12.31</b>
Current	\$ 12,034	9,603
Non-current	4,819	7,517
	<b>\$ 16,853</b>	<b>17,120</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

The Company estimates the financial lease receivables by a simplified approach, that is by measuring lifetime expected credit losses. For this purpose, such financial lease receivables are grouped based on the characteristics of the common credit risks arising from the abilities of representative customers to pay all amounts due under contractual terms, with forward-looking information incorporated, including overall economic and related industry information.

As of December 31, 2025 and 2024, the Company did not have any situations where it was necessary to make provisions for financing lease receivables for losses due to increases in expected credit loss risk.

Please refer to Note 6(26) for information on credit risk.

(VII) Inventory

	<b>2025.12.31</b>	<b>2024.12.31</b>
Medicines and medical materials	<b>\$ 27,241</b>	<b>32,907</b>

Particulars of sales costs of the Company are as follows:

	<b>2025.12.31</b>	<b>2024.12.31</b>
Cost of inventories sold	<b>\$ 1,615,451</b>	<b>1,658,943</b>

(VIII) Disposal of equity method investments

1. The equity method investments of the Company at the reporting date are listed as follows:

	<b>2025.12.31</b>	<b>2024.12.31</b>
Subsidiary	\$ 482,542	542,708
Associate	30,223	-
	<b>\$ 512,765</b>	<b>542,708</b>

2. Subsidiary

Please refer to the 2025 consolidated financial statements.

3. Merger by absorption

The Company resolved at the Board of Directors meeting on December 6, 2024 to conduct a short-form merger with its subsidiary - Medzoneasia Co., Ltd. The merger record date was set on January 1, 2025. The Company is the surviving company, and Medzoneasia Co., Ltd. is the dissolved company.

The details of the identifiable assets acquired and the carrying amounts of the liabilities assumed by the Company on January 1, 2025 are as follows:

	<b>Medzoneasia</b>
Cash and bank deposits	\$ 21,296

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

Accounts receivable, net	1,476
Other receivables, net	2,409
Prepayments	1,985
Financial assets at fair value through other comprehensive income - non-current	27,230
Equity method investments	49,022
Property, plant and equipment	28,748
Right-of-use asset	9,834
Intangible assets	2,411
Other non-current assets	58,708
Short-term loans	(50,000)
Accounts payable, net	(166)
Other payables, net	(6,211)
lease liabilities	(11,804)
Contract liabilities - current	(36,155)
Other current liabilities	(65)
Long-term loans	(30,000)
Other non-current liabilities	(878)
Total identifiable net assets	<u><b>\$ 67,840</b></u>

4. Affiliates

The consolidated financial information of the Company's individually insignificant affiliates that apply the equity method is given below, and amounts included in the Company's Parent Company Only Financial Statements are as follows:

	<b>2025.12.31</b>	<b>2024.12.31</b>
Total carrying amount of equity in individually insignificant affiliates at the end of the period	<u><b>\$ 30,223</b></u>	<u><b>-</b></u>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

	<b>2025</b>	<b>2024</b>
Share attributable to the Company		
Net income for the period	\$ 861	(94)
Other comprehensive income	-	-
Total comprehensive income	<b>\$ 861</b>	<b>(94)</b>

(IX) Changes in ownership interests in subsidiaries

1. Failure to participate in subsidiaries' cash capital increase in proportion to shareholding

The subsidiary of the Company – Min Jian did not subscribe for the cash capital increase of its subsidiary – Sheng Yo Rehabilitative Technologies, in proportion to its shareholding in July 2025, resulting in an increase in its shareholding ratio from 47.62% to 57.18%.

	<b>2025</b>
Decrease in equity attributable to subsidiaries after issuance of new shares	\$ 468
Undistributed earnings	<b>\$ 468</b>

The impact of the above transaction on The Company is as follows:

	<b>2025</b>
Additional paid-in capital - changes in ownership interests in subsidiaries	<b>\$ (287)</b>

2. Subsidiary did not participate in associate's cash capital increase but did not lose significant influence

The subsidiary of the Company – Pregetic Health did not subscribe for the cash capital increase of its associate – Shang Jia Health in proportion to its shareholding in June 2025, resulting in a decrease in its shareholding ratio from 30.82% to 28.18%.

	<b>2025</b>
Increase in equity attributable to subsidiaries after issuance of new shares	\$ 2,688
Capital surplus - share of changes in equity of associates and joint ventures accounted for using the equity method	<b>\$ 2,688</b>

The impact of the above transaction on The Company is as follows:

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

	<b>2025</b>
Additional paid-in capital - changes in ownership interests in subsidiaries	\$ <b>1,026</b>

3. Acquisition of additional equity in subsidiaries

The Company acquired an additional 0.53% equity interest in its subsidiary – Medzoneasia on October 31, 2024, resulting in an increase in its equity interest from 91.47% to 92%.

	<b>2024</b>
Carrying amount of non-controlling interests acquired	\$ 429
Consideration paid to non-controlling interests	(1,500)
Additional paid-in capital - the difference between the price and book value of equity actually acquired and disposed of	\$ <b>(1,071)</b>

4. Subsidiary's buyback and cancellation of treasury stock without loss of control

Medzoneasia bought back 1,500 thousand shares of treasury stock from legal persons after the resolution of the extraordinary shareholders' meeting on December 30, 2024, resulting in an increase in the Company's shareholding ratio from 92.00% to 100.00%. Since there was a difference between the cost of the treasury stock bought back by the subsidiary at NT\$9,000 thousand and the net carrying amount, and there was no change in the Company's control over Medzoneasia, it shall be accounted for as an equity transaction.

The impact of the above transaction on The Company is as follows:

	<b>2024</b>
Decrease in equity attributable to subsidiaries after buyback of treasury shares	\$ (3,304)
Increase in equity in proportion to the equity interest attributable to subsidiaries after buyback of treasury shares	451
Additional paid-in capital-recognized changes in ownership interests in subsidiaries	\$ <b>(2,853)</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

5. No participation in subsidiaries' cash capital increase without loss of control

The subsidiary of the Company – Min Jian did not subscribe for the cash capital increase of its subsidiary - Sheng Yo Rehabilitative Technologies in proportion to its shareholding in January 2024, resulting in a decrease in its shareholding ratio from 90.91% to 47.62%.

	<b>2024</b>
Decrease in equity attributable to subsidiaries after issuance of new shares	\$ 4,240
Undistributed earnings	<b>\$ 4,240</b>

The impact of the above transaction on The Company is as follows:

	<b>2024</b>
Additional paid-in capital - changes in ownership interests in subsidiaries	<b>\$ (2,605)</b>

The Company did not subscribe for shares in the cash capital increase by Precision Health Inc. based on its shareholding ratio in September 2024, resulting in a decrease in its shareholding ratio from 38.90% to 38.19%.

	<b>2024</b>
Decrease in equity attributable to subsidiaries after issuance of new shares	\$ (22,782)
Equity attributable to subsidiaries recognized in the newly issued shares based on their equity ratio after issuance of new shares	23,514
Additional paid-in capital - changes in ownership interests in subsidiaries	<b>\$ 732</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(X) Property, plant and equipment

	Land	Houses and buildings	Machinery and equipment	Office equipment	Leasehold improvements	Other equipment	Leased assets	Unfinished projects and equipment to be accepted	Total
Cost:									
Balance on January 1, 2025	\$ 651,352	514,180	197,157	17,970	38,218	49,003	414,510	-	1,882,390
Acquired through business combination	-	-	-	1,149	-	29,302	-	-	30,451
Increase	-	-	3,242	1,028	124	20,355	29,371	37,916	92,036
Reclassification	-	-	-	-	-	37,916	(47,853)	(37,916)	(47,853)
Disposal	-	-	(6,647)	(1,146)	(11,234)	(241)	(71,106)	-	(90,374)
Balance on December 31, 2025	<u>\$ 651,352</u>	<u>514,180</u>	<u>193,752</u>	<u>19,001</u>	<u>27,108</u>	<u>136,335</u>	<u>324,922</u>	<u>-</u>	<u>1,866,650</u>
Balance on January 1, 2024	\$ 651,352	514,180	180,374	15,443	41,142	45,842	446,971	-	1,895,304
Increase	-	-	23,276	2,993	623	3,193	145	946	31,176
Reclassification	-	-	-	(123)	-	(15)	(67)	(946)	(1,151)
Disposal	-	-	(6,493)	(343)	(3,547)	(17)	(32,539)	-	(42,939)
Balance on December 31, 2024	<u>\$ 651,352</u>	<u>514,180</u>	<u>197,157</u>	<u>17,970</u>	<u>38,218</u>	<u>49,003</u>	<u>414,510</u>	<u>-</u>	<u>1,882,390</u>
Accumulated depreciation:									
Balance on January 1, 2025	\$ -	44,277	169,559	15,240	34,465	16,455	260,529	-	540,525
Acquired through business combination	-	-	-	1,149	-	554	-	-	1,703
Depreciation for the year	-	17,139	11,337	1,906	1,746	9,647	55,041	-	96,816
Reclassification	-	-	823	-	-	-	(48,582)	-	(47,759)
Disposal	-	-	(6,647)	(1,146)	(11,234)	(221)	(68,458)	-	(87,706)
Balance on December 31, 2025	<u>\$ -</u>	<u>61,416</u>	<u>175,072</u>	<u>17,149</u>	<u>24,977</u>	<u>26,435</u>	<u>198,530</u>	<u>-</u>	<u>503,579</u>
Balance on January 1, 2024	\$ -	27,137	157,465	13,043	35,209	12,150	234,035	-	479,039
Depreciation for the year	-	17,140	18,587	2,360	2,803	4,316	51,960	-	97,166
Reclassification	-	-	-	(11)	-	(1)	(12)	-	(24)
Disposal	-	-	(6,493)	(152)	(3,547)	(10)	(25,454)	-	(35,656)
Balance on December 31, 2024	<u>\$ -</u>	<u>44,277</u>	<u>169,559</u>	<u>15,240</u>	<u>34,465</u>	<u>16,455</u>	<u>260,529</u>	<u>-</u>	<u>540,525</u>
Book value:									
December 31, 2025	<u>\$ 651,352</u>	<u>452,764</u>	<u>18,680</u>	<u>1,852</u>	<u>2,131</u>	<u>109,900</u>	<u>126,392</u>	<u>-</u>	<u>1,363,071</u>
December 31, 2024	<u>\$ 651,352</u>	<u>469,903</u>	<u>27,598</u>	<u>2,730</u>	<u>3,753</u>	<u>32,548</u>	<u>153,981</u>	<u>-</u>	<u>1,341,865</u>

Please refer to Note 8 for details of long-term loan guarantees that have been provided as of December 31, 2025 and 2024.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(XI) Right-of-use assets

	<b>Houses and buildings</b>	<b>Transportation equipment</b>	<b>Total</b>
Cost:			
Balance on January 1, 2025	\$ 445,744	12,909	458,653
Increase	-	2,095	2,095
Decrease	(10,705)	(2,524)	(13,229)
Balance on December 31, 2025	<b>\$ 435,039</b>	<b>12,480</b>	<b>447,519</b>
Balance on January 1, 2024	\$ 445,738	19,225	464,963
Increase	-	5,298	5,298
Decrease	-	(11,608)	(11,608)
Reclassification	6	(6)	-
Balance on December 31, 2024	<b>\$ 445,744</b>	<b>12,909</b>	<b>458,653</b>
Accumulated depreciation:			
Balance on January 1, 2025	\$ 169,063	5,723	174,786
Provision for depreciation	42,407	4,176	46,583
Other decreases	(10,705)	(2,524)	(13,229)
Balance on December 31, 2025	<b>\$ 200,765</b>	<b>7,375</b>	<b>208,140</b>
	<b>Houses and buildings</b>	<b>Transportation equipment</b>	<b>Total</b>
Balance on January 1, 2024	\$ 124,782	11,924	136,706
Provision for depreciation	44,281	5,407	49,688
Other decreases	-	(11,608)	(11,608)
Balance on December 31, 2024	<b>\$ 169,063</b>	<b>5,723</b>	<b>174,786</b>
Book value:			
December 31, 2025	<b>\$ 234,274</b>	<b>5,105</b>	<b>239,379</b>
December 31, 2024	<b>\$ 276,681</b>	<b>7,186</b>	<b>283,867</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(XII) Intangible assets

	<b>Management right</b>	<b>Computer software</b>	<b>Total</b>
Cost:			
Balance on January 1, 2025	\$ 69,505	38,820	108,325
Acquired through business combination	-	2,411	2,411
Increase	-	7,268	7,268
Balance on December 31, 2025	<b>\$ 69,505</b>	<b>48,499</b>	<b>118,004</b>
Balance on January 1, 2024	\$ 69,505	35,418	104,923
Increase	-	3,402	3,402
Balance on December 31, 2024	<b>\$ 69,505</b>	<b>38,820</b>	<b>108,325</b>
Accumulated amortization:			
Balance on January 1, 2025	\$ 68,935	35,050	103,985
Amortization for the period	311	4,906	5,217
Balance on December 31, 2025	<b>\$ 69,246</b>	<b>39,956</b>	<b>109,202</b>
Balance on January 1, 2024	\$ 68,624	32,766	101,390
Amortization for the period	311	2,284	2,595
Balance on December 31, 2024	<b>\$ 68,935</b>	<b>35,050</b>	<b>103,985</b>
Carrying amount:			
December 31, 2025	<b>\$ 259</b>	<b>8,543</b>	<b>8,802</b>
December 31, 2024	<b>\$ 570</b>	<b>3,770</b>	<b>4,340</b>

(XIII) Other non-current assets

	<b>2025.12.31</b>	<b>2024.12.31</b>
Refundable deposits	\$ 464,911	318,920
Prepayments for equipment	29,538	-
	<b>\$ 494,449</b>	<b>318,920</b>

Refundable deposits are operational deposits paid by the Company to ensure the performance of obligations of providing medical system institutions with operations management services.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(XIV) Long-term loans

<b>2025.12.31</b>				
	<b>Currency</b>	<b>Interest rate range</b>	<b>Expiration month</b>	<b>Amount</b>
Secured bank loans	New Taiwan Dollars	2.60%	2039.1	836,000
Less: amount due within one year	New Taiwan Dollars			(59,714)
<b>Total</b>				<b>\$ 776,286</b>
Unused quota				<b>\$ -</b>
<b>2024.12.31</b>				
	<b>Currency</b>	<b>Interest rate range</b>	<b>Expiration month</b>	<b>Amount</b>
Secured bank loans	New Taiwan Dollars	2.59%~2.94%	2027.6~2031.4	\$ 860,205
Less: amount due within one year	New Taiwan Dollars			(98,769)
<b>Total</b>				<b>\$ 761,436</b>
Unused quota				<b>\$ 620,000</b>

Please refer to Note 8 for guaranty provided by the Company for bank loans with assets as collateral.

(XV) Lease liabilities

	<b>2025.12.31</b>	<b>2024.12.31</b>
Current	<b>\$ 41,092</b>	<b>\$ 45,295</b>
Non-current	<b>\$ 211,770</b>	<b>\$ 250,982</b>

Please refer to Note (26) Financial Instruments for the maturity analysis.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

The following amounts are recognized in profit or loss:

	<b>2025</b>	<b>2024</b>
Interest expenses on lease liabilities	<b>\$ 5,348</b>	<b>6,157</b>
Variable lease payments not included in the measurement of the lease liabilities	<b>\$ 25,380</b>	<b>24,433</b>
Income from sublease of right-of-use assets	<b>\$ 50,858</b>	<b>53,846</b>
Expenses on short-term and low-value leases	<b>\$ 7,833</b>	<b>5,345</b>

The following amounts are recognized in the cash flow statement:

	<b>2025</b>	<b>2024</b>
Total cash outflows for leases	<b>\$ 84,071</b>	<b>83,624</b>

1. Houses, buildings and transportation equipment

The Company leases houses, buildings, and transportation equipment for operation purposes, typically for a lease term of 3~11 years.

Please refer to Note 6(16) for the Company's subleasing of part of the right-of-use assets with the consent of the lessor under operating leases.

2. Other leases

The Company leases some houses, buildings and transportation equipment which are short-term or low value leases, and elects not to recognize related right-of-use assets and lease liabilities by applying recognition exemption.

(XVI) Operating lease

The Company leases self-owned property, plant and equipment and right-of-use assets under operating leases. Since substantially all the risks and rewards attached to the ownership of the underlying assets have not been transferred, such lease contracts are classified as operating leases. For information on the terms of investment property lease contracts and right-of-use assets, please refer to Note 6(10) Property, Plant and Equipment and Note 11 Right-of-use Assets respectively.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

The maturity analysis of lease payments is presented in the following table based on the total undiscounted lease payments to be received after the reporting date:

	<u>2025.12.31</u>	<u>2024.12.31</u>
1st year	\$ 78,135	96,548
2nd year	14,406	30,290
3rd year	4,683	3,138
4th year	-	465
5th year	-	123
More than 5 years	-	-
	<u><u>\$ 97,224</u></u>	<u><u>130,564</u></u>

For the years ended December 31, 2025 and 2024, the rental revenue from investment properties amounted to NT\$0 thousand and NT\$7,741 thousand, respectively.

(XVII) Other payables

	<u>2025.12.31</u>	<u>2024.12.31</u>
Employee remuneration payable	\$ 52,442	80,374
Salaries and bonuses payable	16,144	20,322
Equipment payables	6,060	2,861
Directors' and supervisors' remuneration payable	1,890	2,669
Business tax payable	3,871	7,193
Others	17,697	21,547
	<u><u>\$ 98,104</u></u>	<u><u>134,966</u></u>

(XVIII) Employee benefits

1. Defined benefit plans

The adjustments to the present value of the Company's defined benefit obligations and the fair value of plan assets are as follows:

	<u>2025.12.31</u>	<u>2024.12.31</u>
Present value of a defined benefit obligation	\$ 10,581	9,558
Fair value of plan assets	(2,713)	(2,291)
Net defined benefit liabilities	<u><u>\$ 7,868</u></u>	<u><u>7,267</u></u>

The defined benefit plans of the Company shall be appropriated to the labor retirement reserve account in the Bank of Taiwan. The pension payment for each employee subject to the Labor Standards Act is calculated based on the base amount corresponding to the years

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

of service and the average salary for the six months prior to retirement.

(1) Composition of plan assets

The pension funds appropriated by the Company in accordance with the Labor Standards Act are managed by the Bureau of Labor Fund Utilization of the Ministry of Labor (hereinafter referred to as the Bureau of Labor Funds). In accordance with the "Regulations on the Custody and Utilization of Labor Retirement Fund Income and Expenditure", the minimum annual final distribution amount of the funds shall not be less than the income calculated based on the two-year fixed deposit interest rate of local banks.

As of the reporting date, the balance of the Company's labor retirement reserve account at Bank of Taiwan was NT\$2,713 thousand. For information on the utilization of labor pension fund assets, including fund yield and fund asset allocation, please refer to the information published on the website of the Bureau of Labor Fund Utilization of the Ministry of Labor.

(2) Changes in the present value of defined benefit obligations

	<b>2025</b>	<b>2024</b>
Defined benefit obligation as of January 1	\$ 9,558	8,965
Servicing costs and interests for the period	518	492
Remeasurement amount of net defined benefit liabilities		
- Actuarial gains and losses arising from changes in financial assumptions	505	115
Benefits paid by the plan	-	(14)
Defined benefit obligation as of December 31	<b>\$ 10,581</b>	<b>9,558</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(3) Changes in fair value of plan assets

	<b>2025</b>	<b>2024</b>
Fair value of plan assets as of January 1	\$ (2,291)	(734)
Interest income	(36)	(12)
Remeasurement amount of net defined benefit liabilities		
- Return on plan assets (excluding current interest)	(135)	(67)
Amount allocated to the plan	(251)	(1,492)
Benefits paid by the plan	-	14
Fair value of plan assets on December 31	<b>\$ (2,713)</b>	<b>(2,291)</b>

(4) Expenses recognized as profit or loss

	<b>2025</b>	<b>2024</b>
Servicing costs for the period	\$ 375	369
Net interest on net defined benefit liabilities	107	111
	<b>\$ 482</b>	<b>480</b>
Operating costs	\$ 193	194
Operating expenses	289	286
	<b>\$ 482</b>	<b>480</b>

(5) Remeasurement amount of net defined benefit liabilities recognized as other comprehensive income

	<b>2025</b>	<b>2024</b>
Accumulated balance as of January 1	\$ 4,485	4,534
Amount recognized in the period	(370)	(49)
Accumulated balance as of December 31	<b>\$ 4,115</b>	<b>4,485</b>

(6) Actuarial assumptions

	<b>2025.12.31</b>	<b>2024.12.31</b>
Discount rate	1.25%	1.50%
Future salary increase	3.25%	3.00%

The Company expects to contribute NT\$280 thousand to the defined benefit plan within one year of the reporting date in 2025.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

The weighted average duration of defined benefit plans is 10.1 years.

(7) Sensitivity analysis

	<b>Impact on defined benefit obligations</b>	
	<b>Increase ratio</b>	<b>Decrease ratio</b>
December 31, 2025		
Discount rate (0.25% change)	\$ (260)	269
Future salary increase (0.25% change)	259	(252)
December 31, 2024		
Discount rate (0.25% change)	(247)	256
Future salary increase (0.25% change)	247	(240)

The sensitivity analysis mentioned above is based on the analysis of the impact of changes in a single assumption while other assumptions remain unchanged. However, changes in many assumptions may be correlated in practice. The sensitivity analysis is conducted by the same method as used to calculate net defined benefit liabilities on the balance sheet.

The methods and assumptions used in the sensitivity analysis for the period are the same as those used in the previous period.

2. Defined contribution plans

The Company adopts the defined contribution plans under which it shall contribute 6% of each employee's monthly salary to the labor pension individual account of the Bureau of Labor Insurance, in accordance with the provisions of the Labor Pension Act. The Company has no legal or constructive obligation to pay additional amounts after contributing a fixed amount to the Bureau of Labor Insurance under this plan.

The pension expenses under the defined contribution plan of the Company in 2025 and 2024 were NT\$7,715 thousand and NT\$6,317 thousand, respectively.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(XIX) Income taxes

1. The income tax expenses of the Company are as follows:

	<b>2025</b>	<b>2024</b>
Income tax expenses for the period		
Income tax expenses generated in the period	\$ 40,417	48,766
Income tax expenses for the period before adjustment	(4,790)	(226)
Deferred tax income	(1,589)	(413)
income tax expense	<b>\$ 34,038</b>	<b>48,127</b>

2. The details of the income tax benefits recognized by the Company under other comprehensive income are as follows:

	<b>2025</b>	<b>2024</b>
Items not reclassified to profit or loss:		
Remeasurement amount of defined benefit plans	\$ 74	9
Unrealized valuation profits and losses on investments in financial assets at fair value through other comprehensive income	53,522	3,226
	<b>\$ 53,596</b>	<b>3,235</b>

	<b>2025</b>	<b>2024</b>
Items that may be reclassified to profit or loss subsequently:		
Exchange difference from translation of the financial statements of foreign operations	\$ 30	(191)

The relationship between the Company's income tax expenses and net income before tax for 2025 and 2024 is reconciled as follows:

	<b>2025</b>	<b>2024</b>
	<b>\$ 175,765</b>	<b>248,224</b>
Income taxes calculated by net profit before tax	\$ 35,153	49,645
Permanent difference	4,205	21,985
Tax-free income	(530)	(23,277)
Overestimation in the previous period	(4,790)	(226)
	<b>\$ 34,038</b>	<b>48,127</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

3. Deferred income tax assets and liabilities

Deferred income tax assets:

	Defined benefit retirement plan	Investment loss recognized using the equity method	Financial assets at fair value through other comprehensive income	Exchange difference from translation of the financial statements of foreign operations	Others	Total
<b>January 1, 2025</b>	\$ 1,699	5,177	-	509	568	7,953
Credited to the income statement	-	1,381	-	-	208	1,589
Debited other comprehensive income	74	-	36,509	30	-	36,613
<b>December 31, 2025</b>	<u>\$ 1,773</u>	<u>6,558</u>	<u>36,509</u>	<u>539</u>	<u>776</u>	<u>46,155</u>
<b>January 1, 2024</b>	\$ 1,690	4,790	-	700	542	7,722
Credited to the income statement	-	387	-	-	26	413
(Debited) Credited to other comprehensive income	9	-	-	(191)	-	(182)
<b>December 31, 2024</b>	<u>\$ 1,699</u>	<u>5,177</u>	<u>-</u>	<u>509</u>	<u>568</u>	<u>7,953</u>

Deferred income tax liabilities:

	Financial assets at fair value through other comprehensive income
<b>January 1, 2025</b>	\$ 17,013
Debited other comprehensive income	(17,013)
<b>December 31, 2025</b>	<u>\$ -</u>
<b>January 1, 2024</b>	20,239
Debited other comprehensive income	(3,226)
<b>December 31, 2024</b>	<u>\$ 17,013</u>

4. The Company's corporate income tax returns have been assessed and approved by the tax authorities up to 2023.

(XX) Capital and other equity

1. Issuance of ordinary shares

As of December 31, 2025 and 2024, the total authorized share capital of the Company was NT\$1,500,000 thousand, with a face value of NT\$10 per share and 150,000 thousand shares in total. The aforementioned total authorized capital is for ordinary shares, with a

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

paid-in capital of NT\$1,376,404 thousand and NT\$1,310,861 thousand, respectively. All issued shares have been paid.

Reconciliation of the Company's outstanding shares for the years 2025 and 2024 is as follows:

(in thousand shares)

	<b>Ordinary shares</b>	
	<b>2025</b>	<b>2024</b>
Beginning retained earnings on January 1	131,086	126,044
Capitalization of earnings to increase the capital		
by	6,554	5,042
Ending retained earnings on December 31	<b>137,640</b>	<b>131,086</b>

On June 16, 2025 and June 24, 2024, the shareholders' meeting of the Company approved through a resolution to issue 6,554 thousand and 5,042 thousand new shares with NT\$65,543 thousand and NT\$50,418 thousand from undistributed earnings for capital increase, respectively. The proposals above for capital increase from earnings have been reported to the Securities and Futures Bureau of the Financial Supervisory Commission and come into effect, with September 1, 2025 and September 2, 2024 as the base date of capital increase respectively. All relevant statutory procedures have been completed.

2. Additional paid-in capital

	<b>2025.12.31</b>	<b>2024.12.31</b>
Premium on issuance of stocks and conversion of corporate bonds	\$ 1,095,196	1,095,196
The difference between the price and book value of subsidiaries' equity actually acquired and disposed of	46,149	45,810
Recognized changes in ownership interests in subsidiaries	2,635	2,235
Lapsed share option	2,896	2,896
Share option for convertible corporate bonds	3,900	3,900
	<b>\$ 1,150,776</b>	<b>1,150,037</b>

According to the Company Act, the realized additional paid-in capital can only be distributed by new shares or in cash in proportion to shareholders' original shares after the additional paid-in capital are used for covering losses. The realized additional paid-in capital

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

mentioned above includes the premium on issuance of stocks exceeding their face value and the income from receiving gifts. According to the Rules Governing the Offering and Issuance of Securities by Issuers, the total amount of additional paid-in capital that shall be appropriated as capital shall not exceed 10% of the paid-in capital each year.

3. Retained earnings

As per the Company's Articles of Incorporation, a surplus in the annual final accounts shall first be appropriated to pay taxes as per the laws to cover accumulated losses, and then 10% of the surplus shall be appropriated as legal reserves, excluding the case where legal reserves have reached the total capital of the Company. The remaining part shall be appropriated or reversed as special reserves according to the laws and regulations. In case of any surplus remained thereafter, the Board of Directors shall prepare a proposal for the distribution of earnings and submit it to the shareholders' regular meeting for resolution on the distribution of dividends to shareholders with surplus and accumulated undistributed earnings.

In consideration of the current and future investment environment, capital needs, profitability, capital structure, future operational needs, as well as the interests of shareholders, balanced dividends and the Company's long-term financial plan, etc., dividends will be distributed in cash or stock. The proportion of dividends distributed in cash to shareholders in the current year shall be no less than 20% of the total dividends in the current year, while the rest shall be distributed in stock dividends. However, the actual distribution proportion may be adjusted according to the actual profit and operating conditions of the current year.

(1) Legal reserves

Where the Company does not suffer any loss, a legal reserve shall be distributed by issuing new shares or in cash, through a resolution of the shareholders' meeting, but only the portion of the legal reserve which exceeds 25% of the paid-in capital may be distributed.

(2) Special reserves

In accordance with the regulations of the Financial Supervisory Commission, for the distribution of distributable earnings, the Company shall appropriate a special reserve from the current profit and loss and the undistributed earnings in the previous period for the difference between the recognized net deduction of other shareholders' equity in the current year and the balance of the special reserve appropriated in the preceding paragraph. The deduction of other shareholders' equity accumulated in the previous period shall be

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

appropriated from undistributed earnings in the previous period to a special reserve and shall not be distributed. If there is a subsequent reversal in the deduction of other shareholders' equity, the reversed amount shall be used for distribution of earnings.

(3) Distribution of earnings

The Company's shareholders' meetings on June 16, 2025 and June 24, 2024 resolved the earnings distribution proposals for 2024 and 2023, respectively, and the amounts of dividends distributed to owners are as follows:

		<b>2024</b>	
		<b>Allotment rate</b>	
		<b>(NT\$)</b>	<b>Amount</b>
Dividends distributed to ordinary shareholders:			
Cash	\$	0.50	65,543
Stock		0.50	65,543
			<b>\$ 131,086</b>

		<b>2023</b>	
		<b>Allotment rate</b>	
		<b>(NT\$)</b>	<b>Amount</b>
Dividends distributed to ordinary shareholders:			
Cash	\$	0.40	50,418
Stock		0.40	50,418
			<b>\$ 100,836</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

4. Other equity (net income after taxes)

	<b>Exchange difference from translation of the financial statements of foreign operations</b>	<b>Unrealized gains or losses on financial assets at fair value through other comprehensive income</b>	<b>Total</b>
Balance on January 1, 2025	\$ (1,338)	48,342	47,004
Exchange difference from translation of the net assets of foreign operations	(122)	-	(122)
Share of unrealized gains or losses of subsidiaries and affiliates applying the equity method on financial assets at fair value through other comprehensive income	-	(1,898)	(1,898)
Share of translation differences of subsidiaries applying the equity method	(698)	-	(698)
Unrealized losses on financial assets at fair value through other comprehensive income	-	(187,593)	(187,593)
Balance on December 31, 2025	<u>\$ (2,158)</u>	<u>(141,149)</u>	<u>(143,307)</u>
Balance on January 1, 2024	\$ (2,507)	125,160	122,653
Exchange difference from translation of the net assets of foreign operations	763	-	763
Share of unrealized gains or losses of subsidiaries and affiliates applying the equity method on financial assets at fair value through other comprehensive income	-	(11,653)	(11,653)
Share of translation differences of subsidiaries applying the equity method	406	-	406
Unrealized valuation losses on financial assets at fair value through other comprehensive income	-	(65,165)	(65,165)
Balance on December 31, 2024	<u>\$ (1,338)</u>	<u>48,342</u>	<u>47,004</u>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(XXI) Earnings per share

	2025	2024
<b>Basic earnings per share:</b>		
Net profits attributable to ordinary equity holders of the Company	<u>\$ 141,727</u>	<u>200,097</u>
Weighted average number of outstanding ordinary shares	<u>137,640</u>	<u>137,640</u>
Basic earnings per share (NT\$)	<u>\$ 1.03</u>	<u>1.45</u>
<b>Diluted earnings per share:</b>		
Net profits attributable to ordinary equity holders of the Company (diluted)	<u>\$ 141,727</u>	<u>200,097</u>
Effects of dilutive potential ordinary shares		
Weighted average number of outstanding ordinary shares (basic)	<u>137,640</u>	<u>137,640</u>
Effects of employee remuneration in stock	<u>596</u>	<u>625</u>
Weighted average number of outstanding ordinary shares (diluted)	<u>138,236</u>	<u>138,265</u>
Diluted earnings per share (NT\$)	<u>\$ 1.03</u>	<u>1.45</u>

(XXII) Revenue from customer contracts

1. Disaggregation of revenue

	2025			
	Sales of goods	Service provision	Leases	Total
Main regional markets:				
Taiwan	<u>\$ 1,714,633</u>	<u>600,248</u>	<u>76,300</u>	<u>2,391,181</u>
Main product/service lines:				
Medicines and medical materials	1,714,633	-	-	1,714,633
Health care management	-	556,808	-	556,808
Equipment leases	-	-	71,508	71,508
Leases of investment properties	-	-	4,792	4,792
Others	-	43,440	-	43,440

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

	<b>\$ 1,714,633</b>	<b>600,248</b>	<b>76,300</b>	<b>2,391,181</b>
	<b>2024</b>			
	<b>Service</b>			
	<b>Sales of goods</b>	<b>provision</b>	<b>Leases</b>	<b>Total</b>
Main regional markets:				
Taiwan	<b>\$ 1,776,015</b>	<b>519,998</b>	<b>112,297</b>	<b>2,408,310</b>
Main product/service lines:				
Medicines and medical materials	\$ 1,776,015	-	-	1,776,015
Health care management	-	519,998	-	519,998
Equipment leases	-	-	76,028	76,028
Leases of investment properties and properties	-	-	36,269	36,269
	<b>\$ 1,776,015</b>	<b>519,998</b>	<b>112,297</b>	<b>2,408,310</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

2. Contract balances

	<b>2025.12.31</b>	<b>2024.12.31</b>	<b>2024.1.1</b>
Notes receivable	\$ 787	547	703
Accounts receivable	60,676	67,429	49,429
Accounts receivable - related parties	1,054,752	937,376	1,069,349
Finance lease receivables	6,253	-	277
Finance lease receivables - related parties	5,781	9,603	10,498
Long-term finance lease receivables	567	-	-
Long-term finance lease receivables - related parties	4,252	7,517	15,970
Less: loss allowances	(1)	(219)	(216)
	<b>\$ 1,133,067</b>	<b>1,022,253</b>	<b>1,146,010</b>

Please refer to Note 6(4) and (6) for the disclosure of notes and accounts receivable (including related parties) and their impairment.

(XXIII) Remuneration to employees and directors

The Company's Articles of Incorporation were amended on June 16, 2025, pursuant to a resolution of the shareholders' meeting. Under the revised Articles, if the Company realizes a profit in a given year, 6% to 10% of the profit shall be allocated as employee compensation (with no less than 10% of this amount distributed to rank-and-file employees), and no more than 3% shall be allocated as compensation for directors and supervisors. However, the allowances for the Company's accumulated losses shall be set aside from the profit first. The objects to which the employees' remuneration referred to in the preceding paragraph is paid in stock or cash include employees of affiliated companies who meet certain requirements. Under the previous Articles of Incorporation, if a profit was realized in a year, 6% to 10% of the profit was to be allocated as employee remuneration, and no more than 3% as directors' remuneration. However, the allowances for the Company's accumulated losses shall be set aside from the profit first. The objects to which the employees' remuneration referred to in the preceding paragraph is paid in stock or cash include employees of affiliated companies who meet certain requirements.

The estimated amounts of employees' remuneration of the Company recognized in 2025 and 2024 were NT\$11,340 thousand and NT\$16,014 thousand, respectively, and the estimated amounts of directors' remuneration were NT\$1,890 thousand and NT\$2,669 thousand,

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

respectively. The estimates were based on the Company's net profit before tax in that period less employees' and directors' remuneration, multiplied by the distribution percentages of employees' and directors' remuneration as stipulated in the Company's Articles of Incorporation, and the remuneration was presented in operating expenses for that period. In case of a difference between the actual distribution amount in the following year and the estimated amount recognized, it shall be accounted for as changes in accounting estimates and recognized in profit or loss for the following year.

In 2024 and 2023, the Company appropriated NT\$16,014 thousand and NT\$11,194 thousand respectively for employee remuneration, and NT\$2,669 thousand and NT\$1,866 thousand respectively for directors' remuneration, which did not differ from the resolutions on distribution of employees' and directors' remuneration by the Company's Board of Directors in 2024 and 2023. Relevant information can be found on the MOPS.

(XXIV) Other net income and expenses

Other net income and expenses of the Company in 2025 and 2024 are as follows:

	<u>2025</u>	<u>2024</u>
Revenue from subleases of right-of-use assets	\$ 37,823	37,666
Net gains on disposal and retirement of properties, plants and equipment	7,286	118,256
	<u>\$ 45,109</u>	<u>155,922</u>

(XXV) Non-operating income and expenses

1. Interest income

	<u>2025</u>	<u>2024</u>
Bank deposit interest	\$ 6,928	5,715
Other interest income	769	732
	<u>\$ 7,697</u>	<u>6,447</u>

2. Other income

	<u>2025</u>	<u>2024</u>
Dividend income	\$ 2,652	46,287
Others	8,820	6,847
	<u>\$ 11,472</u>	<u>53,134</u>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

3. Other gains and losses

	<b>2025</b>	<b>2024</b>
(Losses) gains on financial assets at fair value through profit or loss	\$ (3,712)	8,315
Foreign exchange losses (gains)	(2)	4
Others	(36)	-
	<b>\$ (3,750)</b>	<b>8,319</b>

4. Finance costs

	<b>2025</b>	<b>2024</b>
Interest on loans from financial institutions	\$ 22,256	26,398
Amortization of syndication fees	-	2,886
Amortization of interest on lease liabilities	5,348	6,157
	<b>\$ 27,604</b>	<b>35,441</b>

(XXVI) Financial instruments

1. Credit risk

(1) Exposure to credit risk

The carrying amount of a financial asset represents the maximum exposure to credit risk.

(2) Concentration of credit risks

The credit risks of the Company are mainly on its largest customers. As of December 31, 2025 and 2024, 72% and 80% of the balance of accounts receivable were owed by the largest customers, which indicates a significant concentration of the Company's credit risks.

(3) Credit risk of accounts receivable

Please refer to Note 6(4) and (6) for information on the exposure of notes and accounts receivable and finance lease receivables to credit risk.

Other financial assets measured at amortized cost include other receivables, restricted bank deposits and refundable deposits.

The other receivables, restricted bank deposits and refundable deposits held by the Company are considered to be of low credit risk as the counterparties and other performing parties are creditworthy or financial institutions rated investment grade or above.

The Company made no provision of loss allowance for other receivables, restricted bank deposits and refundable deposits measured at amortized cost as of December 31, 2025 and 2024 due to increased 12-month expected credit losses.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

2. Liquidity risk

The contractual maturities of financial liabilities are showed in the following table, including the effect of estimated interest but excluding the effect of netting agreements.

	Carrying amount	Contractual cash flows	To be paid immediately or within 1 month	Within 6 months	6-12 months	1-3 years	Over 3 years
<b>December 31, 2025</b>							
Non-derivative financial liabilities							
Non-interest bearing liabilities	\$ 616,912	616,912	262,318	339,484	15,110	-	-
lease liabilities	252,862	268,891	4,136	20,512	20,992	83,753	139,498
Floating rate instruments	836,000	990,869	1,811	38,817	40,240	157,078	752,923
	<b>\$ 1,705,774</b>	<b>1,876,672</b>	<b>268,265</b>	<b>398,813</b>	<b>76,342</b>	<b>240,831</b>	<b>892,421</b>
<b>December 31, 2024</b>							
Non-derivative financial liabilities							
Non-interest bearing liabilities	\$ 641,608	641,608	297,467	329,947	14,194	-	-
lease liabilities	296,277	317,606	4,413	21,421	24,800	86,186	180,786
Floating rate instruments	860,205	914,392	2,935	60,328	60,672	764,544	25,913
	<b>\$ 1,798,090</b>	<b>1,873,606</b>	<b>304,815</b>	<b>411,696</b>	<b>99,666</b>	<b>850,730</b>	<b>206,699</b>

The Company does not expect a significantly earlier occurrence of cash flows based on the due date analysis or significant differences between the actual amounts and estimates.

3. Exchange rate risk

(1) Exposure to exchange rate risk

The financial assets and liabilities of the Company exposed to significant foreign currency exchange rate risk are as follows:

	2025.12.31			2024.12.31		
	Foreign currency	Exchange rate (NT\$)	New Taiwan Dollars	Foreign currency	Exchange rate (NT\$)	New Taiwan Dollars
<u>Financial asset</u>						
<u>Non-monetary items</u>						
USD	\$ 10,547	31.430	331,492	10,547	32.785	345,783
CNY	4,585	4.496	20,614	5,948	4.478	26,635

(2) Sensitivity analysis

The exchange rate risk of the Company mainly comes from cash and cash equivalents as well as accounts and borrowings receivable denominated in foreign currencies, which generate foreign currency exchange gains and losses during translation. On December 31, 2025 and 2024, if New Taiwan dollar appreciated and depreciated by

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

5% against USD and RMB, while all other factors remained unchanged, the net profit before tax in 2025 and 2024 would have decreased or increased by NT\$17,605 thousand and NT\$18,621 thousand, respectively. The analysis of the two periods is conducted on the same basis.

Due to the large variety of functional currencies among the Company, the exchange gains or losses on monetary items are disclosed in aggregate. Foreign exchange (losses) gains, including both realized and unrealized amounts, amounted to NT\$(2) thousand and NT\$4 thousand for the years ended December 31, 2025 and 2024, respectively.

**4. Interest rate analysis**

The exposure of the Company's financial liabilities to interest rate risk is illustrated in Liquidity Risk Management section in this note.

The sensitivity analysis below is based on the exposure of non-derivative instruments to interest rate risk at the reporting date. The analysis of floating rate liabilities is based on the assumption that the outstanding liabilities at the reporting date are outstanding throughout the year. The rate of change in the interest rate reported to major management personnel of the Company is the interest rate plus or minus 20 basis points, which also represents the management's evaluation on the reasonably possible range of changes in the interest rate.

If the interest rate increased or decreased by 20 basis points, while all other variables remain unchanged, the pre-tax net profit of the Company for 2025 and 2024 would have increased or decreased by NT\$1,672 thousand and NT\$1,720 thousand, mainly due to changes in the interest rate of the Company's floating rate loans.

**5. Information on fair values**

**Type and fair value of financial instruments**

The Company's financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income are measured at fair value on a recurring basis. The carrying amounts and fair values of all types of financial assets and financial liabilities (including fair value level information, but for financial instruments not measured at fair value with carrying amounts reasonably approximate to their fair values as well as lease liabilities, fair value information is not required to be disclosed according to the regulations) are listed as follows:

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

	2025.12.31				
	Carrying amount	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss:					
Fund beneficiary certificate	\$ 10,769	10,769	-	-	10,769
Non-TWSE/TPEX listed stocks	227	227	-	-	227
Non-TWSE/TPEX listed stocks	23,983	-	-	23,983	23,983
Subtotal	<u>34,979</u>	<u>10,996</u>	<u>-</u>	<u>23,983</u>	<u>34,979</u>
Financial assets at fair value through other comprehensive income					
Non-TWSE/TPEX listed stocks	179,232	-	-	179,232	179,232
Foreign listed stocks	87,264	87,264	-	-	87,264
Limited partnership equity	96,541	-	-	96,541	96,541
Subtotal	<u>363,037</u>	<u>87,264</u>	<u>-</u>	<u>275,773</u>	<u>363,037</u>
Financial assets at amortized cost					
Cash and cash equivalents	948,146	-	-	-	-
Restricted bank deposits	30,000	-	-	-	-
Notes and accounts receivable (including related parties)	1,116,214	-	-	-	-
Other receivables (including related parties)	5,188	-	-	-	-
Finance lease receivables (including those due within one year)	16,853	-	-	-	-
Subtotal	<u>2,116,401</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u><b>\$ 2,514,417</b></u>	<u><b>98,260</b></u>	<u><b>-</b></u>	<u><b>299,756</b></u>	<u><b>398,016</b></u>
Financial liabilities at amortized cost					
Notes and accounts payable (including related parties)	\$ 517,971	-	-	-	-
Other payables (including related parties)	98,941	-	-	-	-
Lease liabilities (including those due within one year)	252,862	-	-	-	-
Long-term loans (including those due within one year)	836,000	-	-	-	-
Total	<u><b>\$ 1,705,774</b></u>	<u><b>-</b></u>	<u><b>-</b></u>	<u><b>-</b></u>	<u><b>-</b></u>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

	2024.12.31				
	Carrying amount	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss:					
Fund beneficiary certificate	\$ 10,610	10,610	-	-	10,610
Non-TWSE/TPEX listed stocks	27,853	-	-	27,853	27,853
Subtotal	<u>38,463</u>	<u>10,610</u>	<u>-</u>	<u>27,853</u>	<u>38,463</u>
Financial assets at fair value through other comprehensive income					
Non-TWSE/TPEX listed stocks	136,232	-	-	136,232	136,232
Non-overseas listed stocks	345,774	-	-	345,774	345,774
Limited partnership equity	98,744	-	-	98,744	98,744
Subtotal	<u>580,750</u>	<u>-</u>	<u>-</u>	<u>580,750</u>	<u>580,750</u>
Financial assets at amortized cost					
Cash and cash equivalents	984,469	-	-	-	-
Restricted bank deposits	30,000	-	-	-	-
Notes and accounts receivable (including related parties)	1,005,133	-	-	-	-
Other receivables (including related parties)	244,035	-	-	-	-
Finance lease receivables (including those due within one year)	17,120	-	-	-	-
Subtotal	<u>2,280,757</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 2,899,970</u>	<u>10,610</u>	<u>-</u>	<u>608,603</u>	<u>619,213</u>
Financial liabilities at amortized cost					
Notes and accounts payable (including related parties)	\$ 505,028	-	-	-	-
Other payables (including related parties)	136,580	-	-	-	-
Lease liabilities (including those due within one year)	296,277	-	-	-	-
Long-term loans (including those due within one year)	860,205	-	-	-	-
Total	<u>\$ 1,798,090</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

(1) Valuation techniques for fair value of financial instruments measured at fair value

If there is a quoted price in an active market for a financial instrument, that price shall be used for measuring fair value. The market prices, announced by the main exchanges and the over-the-counter trading center for central government bonds that are judged to be popular, are the basis for the fair value of listed equity instruments and the debt instruments with a quoted price in an active market. If a quoted price for a financial instrument can be obtained from exchanges, brokers, underwriters, industry associations, pricing service institutions or competent authorities in a timely manner and on a regular basis, and represents actual fair market transactions with sufficient frequency, it is determined that there is a quoted price in an active market for the financial instrument. Where the above conditions are not met, the market is considered inactive. Generally

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

speaking, a large bid-ask spread, a significant increase in bid-ask spread, or a low transaction volume indicates an inactive market.

The fair values of financial instruments held by the Company without an active market are presented below by type and attribute:

- Equity instruments without quoted prices: The fair value is estimated using the market comparable company method and asset method, with the assumptions mainly based on the ratio of the estimated market price to earnings per share of the investee, the earnings multiplier derived from quoted market prices of comparable TWSE/TPEX listed companies, as well as the equity value of net assets. The estimate has adjusted the effect of discount of the equity securities due to lack of market liquidity.

(2) Transfers between Level 1 and Level 3

The shares of BenQ BM Holding Cayman Corporation held by the Company are classified as financial assets at fair value through other comprehensive income. The fair values as of December 31, 2025 and 2024 were NT\$87,264 thousand and NT\$345,774 thousand, respectively.

As of December 31, 2024, since there was no quoted price in an active market for the shares and the fair value was measured using significant unobservable inputs, they were classified as Level 3. In December 2025, the shares of BenQ BM Holding Cayman Corporation were listed, and became quoted in an active market; therefore, as of December 31, 2025, the fair value measurement was transferred from Level 3 to Level 1.

There were no transfers in 2024.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(3) Table of Changes in Level 3

	<b>Non-derivative financial assets mandatorily measured at fair value through profit or loss</b>	<b>Equity instruments without quoted prices measured at fair value through other comprehensive income</b>
January 1, 2025	\$ 27,853	580,750
Total gains or losses		
Recognized in profit or loss	(3,870)	-
Recognized in other comprehensive income	-	(241,114)
Acquired through merger	-	27,230
Purchase	-	9,614
Capital returned due to capital reduction	-	(13,443)
December 31, 2025	<u>\$ 23,983</u>	<u>363,037</u>
January 1, 2024	\$ 19,684	610,670
Total gains or losses		
Recognized in profit or loss	8,169	-
Recognized in other comprehensive income	-	(68,390)
Purchase	-	42,510
Capital returned due to capital reduction	-	(4,040)
December 31, 2024	<u>\$ 27,853</u>	<u>580,750</u>

The above total gains or losses are presented in "other gains and losses" and "unrealized valuation gains (losses) on financial assets measured at fair value through other comprehensive income". Among them, those related to the assets still held on December 31, 2025 and 2024 are as follows:

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

	<b>2025</b>	<b>2024</b>
Total gains or losses		
Recognized in profit or loss (presented in "other gains and losses")	\$ (3,870)	8,169
Recognized in other comprehensive income (presented in "unrealized valuation gains (losses) on financial assets measured at fair value through other comprehensive income")	(241,114)	(68,390)

(4) Quantitative information on significant unobservable inputs (level 3) used for fair value measurement.

The inputs of fair value measurement of the Company categorized into level 3 mainly comprise financial assets at fair value through other comprehensive income - equity securities investment and financial derivatives. Most of the fair values of the Company categorized into level 3 are with only a single significant unobservable input except that equity instrument investments without an active market are with multiple significant unobservable inputs. Significant unobservable inputs of equity instrument investments without an active market are independent of each other, without any correlation among them.

6. Analysis of the sensitivity of fair value to reasonably possible alternative assumptions for measurement of level 3 fair values

The fair value measurement of financial instruments by the Company is reasonable, whereas different valuation models or parameters used for measurement may result in different valuation results. The impact of the changes in evaluation parameters for financial instruments categorized into Level 3 on profits and losses or other comprehensive income for the period is as follows:

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

	Input value	Upward or downward changes	Changes in fair value reflected in profit or loss		Changes in fair value reflected in other comprehensive income	
			Favorable changes	Adverse changes	Favorable changes	Adverse changes
<b>December 31, 2025</b>						
Financial assets at fair value through profit or loss						
Non-TWSE/TPEX listed stocks	Liquidity discount	5%	\$ 1,499	(1,499)	-	-
Financial assets at fair value through other comprehensive income						
Non-TWSE/TPEX and non-overseas listed stocks	Liquidity discount	5%	-	-	13,424	(13,424)
<b>December 31, 2024</b>						
Financial assets at fair value through profit or loss						
Non-TWSE/TPEX listed stocks	Liquidity discount	5%	1,740	(1,740)	-	-
Financial assets at fair value through other comprehensive income						
Non-TWSE/TPEX and non-overseas listed stocks	Liquidity discount	5%	-	-	25,667	(40,545)

Favorable and adverse changes for the Company refer to fluctuations in fair value, which are calculated by using valuation techniques based on different degrees of unobservable input parameters. For a financial instrument whose fair value is affected by more than one input, the above table only reflects the impact of changes in a single input, and the correlation and variability among the inputs are not taken into account.

(XXVII) Financial risk management

1. Overview

The Company is exposed to the following risks due to the use of financial instruments:

- (1) Credit risk
- (2) Liquidity risk
- (3) Market risk

This note presents the information on the Company's exposure to the above risks, as well as its objectives, policies and procedures for measuring and managing the risks. For further quantitative disclosures, please refer to the respective notes to the Parent Company Only Financial Statements.

2. Risk management framework

The Management Department of the Company analyzes and manages the financial risks related to the operation of the Company based on the degree and breadth of the risks.

3. Credit risk

Credit risk refers to the risk of financial losses of the Company due to the failure to

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

perform contractual obligations by customers or counterparties of financial instruments, mainly from the Company's accounts receivable due from customers and securities investments.

(1) Accounts receivable and other receivables

The management of the Company assigns a dedicated team responsible for the determination of credit lines, credit approval and other monitoring procedures to ensure that appropriate actions have been taken to recover overdue receivables. The Company reviews the recoverable amounts of receivables separately at the reporting date to ensure that appropriate impairment losses have been provisioned for uncollectible receivables.

(2) Investment

The credit risk of bank deposits and other financial instruments is measured and monitored by the management of the Company. The counterparties and other performing parties of the Company are creditworthy or financial institutions rated investment grade or above, which generates no major doubt for performance of the contract, so the Company faces no significant credit risk.

4. Liquidity risk

The Company manages and maintains sufficient cash and cash equivalents for various positions to support the operation of the Company and mitigate the impact of cash flow fluctuations. The management of the Company supervises the use of bank credit lines and ensures compliance with the terms of the loan contracts.

Bank loans and the issuance of commercial paper are important sources of liquidity for the Company. As of December 31, 2025 and 2024, the Company had unused credit facilities amounting to NT\$785,000 thousand and NT\$1,324,358 thousand, respectively.

5. Market risk

(1) Interest rate risk

Market risk refers to the risk that changes in market prices, such as changes in exchange rates, interest rates, and the price of equity instruments, may affect the Company's income or the value of financial instruments held by it. The objective of market risk management is to maintain acceptable levels of market risk exposure and optimize investment returns.

(2) Other market price risks

The Company is exposed to equity price risk arising from the investments in TPEX listed equity securities. Such equity investments not held for trading are strategic investments. The Company does not actively trade these investments, and its management

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

manages the risks by holding various risk-based portfolios.

(XXVIII) Capital management

By capital management, the Company ensures continuing operation of all companies in the Group, and maximizes shareholder returns by optimizing the balance of debt and equity.

The capital structure of the Company is composed of its net debt (i.e., loans less cash and cash equivalents) and equity (i.e., share capital, additional paid-in capital, retained earnings and other equity items). The Company balances its overall capital structure by paying dividends, issuing new shares, repurchasing shares, and issuing new debts or repaying old debts, based on the recommendations of the key management personnel.

(XXIX) Investing and financing activities of non-cash transactions

Investing and financing activities of non-cash transactions performed by the Company in 2025 and 2024.

1. Please refer to Note 6(11) for details on obtaining the right-of-use assets through leasing.
2. Cash paid for purchase of property, plant and equipment is as follows:

	<b>2025</b>	<b>2024</b>
Acquisition of property, plant and equipment	\$ 92,036	31,176
Net changes in equipment pre-payments in subsidiaries	25,906	-
Net changes in equipment payables in subsidiaries	(3,779)	11,194
Cash paid	<b>\$ 114,163</b>	<b>42,370</b>

3. Cash received from disposal of property, plant and equipment is as follows:

	<b>2025</b>	<b>2024</b>
Disposal of property, plant and equipment	\$ 12,154	301,881
Add: Equipment receivable at beginning of period (recognized as other receivables - related parties)	240,000	-
Less: Equipment proceeds receivable (recognized as other receivables- related parties)	(2,200)	(240,000)
Cash received	<b>\$ 249,954</b>	<b>61,881</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

4. The adjustments to liabilities from financing activities are as follows:

	<u>2025.1.1</u>	<u>Cash flows</u>	<u>Changes in non-cash items</u>		<u>2025.12.31</u>
			<u>Lease changes</u>	<u>Acquired through merger</u>	
Short-term loans	\$ -	(50,000)	-	50,000	-
Long-term loans (including those due within one year)	860,205	(54,205)	-	30,000	836,000
Deposits received	15,859	(8,451)	-	878	8,286
Lease liabilities (including those due within one year)	296,277	(45,510)	2,095	-	252,862
	<u><b>\$ 1,172,341</b></u>	<u><b>(158,166)</b></u>	<u><b>2,095</b></u>	<u><b>80,878</b></u>	<u><b>1,097,148</b></u>

	<u>2024.1.1</u>	<u>Cash flows</u>	<u>Changes in non-cash items</u>		<u>2024.12.31</u>
			<u>Lease changes</u>	<u>Others</u>	
Short-term loans	\$ 50,000	(50,000)	-	-	-
Long-term loans (including those due within one year)	956,088	(95,883)	-	-	860,205
Deposits received	15,438	421	-	-	15,859
Lease liabilities (including those due within one year)	338,668	(47,689)	5,298	-	296,277
	<u><b>\$ 1,360,194</b></u>	<u><b>(193,151)</b></u>	<u><b>5,298</b></u>	<u><b>-</b></u>	<u><b>1,172,341</b></u>

**VII. Transactions of Related Parties**

(I) Parent company and ultimate controlling party

Minsheng Medical Holding Co., Ltd., the parent company of the Company, holds 28.79% of the Company's outstanding ordinary shares.

(II) Name of and relationship with related parties

The related parties who have traded with the Company during the period covered by the Parent Company Only Financial Statements are as follows:

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

<u>Name of the related party</u>	<u>Relationship with the Company</u>
Min-Sheng Medical Holding Co., Ltd.	Parent company
Chungyuan Medical Management Co., Ltd.	Subsidiary
Precision Health Inc. (hereinafter referred to as Pregetic Health)	Subsidiary
Hung-Han Medical Health Co., Ltd. (hereinafter referred to as Hung-Han)	Subsidiary (Note 1)
Harvard Health Inc. (hereinafter referred to as Harvard Health, formerly known as Fu Yi Health Management Consulting Co., Ltd.)	Subsidiary (Note 1)
Hanting Digital Technology Co., Ltd. (hereinafter referred to as Hanting)	Substantial related party
Medzoneasia Co., Ltd. (hereinafter referred to as Medzoneasia)	Subsidiary (Note 2)
Mytrex Health Technologies, Inc. (hereinafter referred to as Mytrex Health)	Subsidiary
Mytrex Industries Inc.	Subsidiary
Mytrex USA Co.	Subsidiary (Note 3)
Sheng Yo Rehabilitative Technologies, Inc.	Subsidiary (Note 4)
Macro Global Corporation (hereinafter referred to as Macro Global)	Subsidiary
ShareHope Medicine (HongKong) Co., Ltd.	Subsidiary
Minsheng (Tianjin) Investment Management Co., Ltd.	Subsidiary
Min-Sheng Asia-Pacific (Beijing) Enterprise Management Co., Ltd.	Subsidiary
Shengshi Digital Health Co., Ltd. (formerly known as Shengshih Technology Co., Ltd.)	Subsidiary

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

<u>Name of the related party</u>	<u>Relationship with the Company</u>
Digimed Co., Ltd.	Subsidiary
TECHGROUP Integrate Design Co., Ltd.	Subsidiary
YES Health Co., Ltd. (hereinafter referred to as YES Health)	Subsidiary
CRAFTION INC.	Substantial related party (a non-related party since the Q2 of 2025)
Air Long-Term Care Co., Ltd.	Substantial related party
Min-Sheng Asset Management Co., Ltd. (hereinafter referred to as Min-Sheng Asset)	Substantial related party
Pisheng Construction Co., Ltd. (hereinafter referred to as Pisheng Construction)	Substantial related party
Min-Sheng General Hospital	Substantial related party (Missioncare Corp. system)
Longtan Min-Sheng Hospital	Substantial related party (Missioncare Corp. system)
Dayuan Min-Sheng Hospital	Substantial related party (Missioncare Corp. system)
Home Nursing Center attached to Tayuan Minsheng Hospital	Substantial related party (Missioncare Corp. system)
Pochih Cultural and Creative Co., Ltd.	Substantial related party
Pohui Biotechnology Co., Ltd.	Substantial related party
Po'en Management Consulting Co., Ltd.	Substantial related party
Shengli Management Consulting Co., Ltd. (hereinafter referred to as Shengli Management)	Substantial related party
Shengyu Health Technologies Co., Ltd.	Substantial related party
Chiehpang Technology Co., Ltd.	Substantial related party
Employee Clinic of Hsinchu Science and Industry Park	Substantial related party
United Medical Foundation	Substantial related party
Hafo Clinic	Substantial related party
Fuying Clinic	Substantial related party
Zhiyi Clinic	Substantial related party
Shengyu Clinic	Substantial related party
Hung-jen Yang	Management personnel (Chairperson of the Company)
Min-Sheng Yang	The management
Ming-Hsun Wu	The management

(Note 1): On July 1, 2025, Precision Health Inc. completed a short-form merger with its subsidiaries Harvard Health Inc. and Hung-Han Medical Health Co., Ltd., and Harvard Health Inc. and Hung-Han Medical Health Co., Ltd. were the dissolved companies.

(Note 2): On January 1, 2025, the Company completed a short-form merger with its subsidiary Medzoneasia Co., Ltd., and Medzoneasia Co., Ltd. was the dissolved company.

(Note 3): Mytrex USA Co. was dissolved in August 2025; therefore, it has not been a related party since the fourth quarter of 2025.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(Note 4): Sheng Yo Rehabilitative Technologies, Inc. was dissolved in December 2025; therefore, it has not been a related party since the fourth quarter of 2025.

(III) Significant transactions with related parties

1. Sales of goods

<b>Category of the related party</b>	<b>Operating revenue</b>	
	<b>2025</b>	<b>2024</b>
Substantial related party		
Min-Sheng General Hospital	\$ 1,048,806	1,130,928
Others	84,084	76,541
Subsidiary		
YES Health Co., Ltd.	290,091	202,478
	<b>\$ 1,422,981</b>	<b>1,409,947</b>

The sales price determined by the Company for the above-mentioned related party is the purchase cost plus 5% or more, with the payment term being net 90 to 180 days.

2. Service provision

<b>Category of the related party</b>	<b>Operating revenue</b>	
	<b>2025</b>	<b>2024</b>
Substantial related party		
Min-Sheng General Hospital	\$ 449,072	401,980
Others	35,230	23,059
Subsidiary		
Parent company	1,146	-
	440	-
	<b>\$ 485,888</b>	<b>425,039</b>

The Company's service revenue from the above-mentioned related parties mainly arises from undertaking health examination and testing services, as well as catering and accommodation, in cooperation with medical institutions. Contracts are entered into upon mutual agreement between both parties, with payment terms ranging from 30 to 180 days.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

3. Leases

<u>Category of the related party</u>	<b>Operating revenue</b>	
	<u>2025</u>	<u>2024</u>
Substantial related party		
Min-Sheng General Hospital	\$ 56,468	57,572
Dayuan Min-Sheng Hospital	2,432	8,120
Zhiyi Clinic	4,762	8,032
Others	1,428	2,050
Subsidiary		
Precision Health Inc.	1,451	2,437
YES Health Co., Ltd.	1,574	500
Mytrex Health Technologies, Inc.	23	-
Medzoneasia	-	22,862
	<b><u>\$ 68,138</u></b>	<b><u>101,573</u></b>

The rent paid by the Company to the above-mentioned related party is defined in a lease contract entered into by the two parties by mutual agreement, with the payment period ranging from 30 to 120 days.

<u>Category of the related party</u>	<b>Operating costs and operating expenses - rent expenses</b>	
	<u>2025</u>	<u>2024</u>
Substantial related party - Min-Sheng General Hospital	\$ 1,223	1,217
Substantial related party - Minsheng Asset Company	796	184
Subsidiary - Precision Health Inc.	1,429	543
Subsidiary - Harvard Health Inc.	1,429	2,143
Parent company	477	473
	<b><u>\$ 5,354</u></b>	<b><u>4,560</u></b>

The Company pays monthly rent to the above-mentioned related party in accordance with the general market conditions.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

4. Purchase of goods

<b>Category of the related party</b>	<b>Operating costs</b>	
	<b>2025</b>	<b>2024</b>
Subsidiary	<b>\$ 1,656</b>	<b>1,507</b>

The prices and payment terms for goods purchased by the Company from the above-mentioned related party are not significantly different from those for general manufacturers, with a payment term of 30 to 120 days upon acceptance.

5. Receivables due from related parties

<b>Category of the related party</b>	<b>Account items</b>	<b>2025.12.31</b>	<b>2024.12.31</b>
Subsidiary			
YES Health Co., Ltd.	Accounts receivable	\$ 182,481	54,732
Precision Health Inc.	Finance lease receivables	455	-
Precision Health Inc.	Long-term finance lease receivables	673	-
Medzoneasia	Finance lease receivables	-	97
Medzoneasia	Long-term finance lease receivables	-	60
Medzoneasia	Other receivables	-	1,023
Hanting Company	Other receivables	2,200	-
Others	Other receivables	49	41
Substantial related party			
Min-Sheng General Hospital	Accounts receivable	811,785	838,718
Others	Accounts receivable	60,485	43,707
Min-Sheng General Hospital	Finance lease receivables	990	3,308
Longtan Min-Sheng Hospital	Finance lease receivables	1,009	1,508
Dayuan Min-Sheng Hospital	Finance lease receivables	2,348	2,209
Zhiyi Clinic	Finance lease receivables	979	2,481
Min-Sheng General Hospital	Long-term finance lease receivables	-	188
Longtan Min-Sheng Hospital	Long-term finance lease receivables	517	880
<b>Category of the</b>	<b>Account items</b>	<b>2025.12.31</b>	<b>2024.12.31</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

<b>related party</b>			
Dayuan Min-Sheng Hospital	Long-term finance lease receivables	\$ 3,062	5,411
Zhiyi Clinic	Long-term finance lease receivables	-	978
Min-Sheng General Hospital	Other receivables	85	85
Dayuan Min-Sheng Hospital	Other receivables	28	240,000
Zhiyi Clinic	Other receivables	395	53
Others	Other receivables	22	23
		<b>\$ 1,067,563</b>	<b>1,195,502</b>

6. Payables to related parties

<b>Category of the related party</b>	<b>Account items</b>	<b>2025.12.31</b>	<b>2024.12.31</b>
Substantial related party			
Others	Accounts payable	\$ 469	178
Min-Sheng General Hospital	Other payables	546	832
Others	Other payables	291	416
Subsidiary	Accounts payable	548	590
Subsidiary	Other payables	-	366
		<b>\$ 1,854</b>	<b>2,382</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

7. Others

<b>Category of the related party</b>	<b>Account items</b>	<b>2025</b>	<b>2024</b>
Parent company	Other income and losses - rental income	\$ 589	583
Substantial related party			
Min-Sheng General Hospital	Operating cost - other expenses	466	1,330
Min-Sheng General Hospital	Other income and losses - rental income	29,333	29,054
Others	"	72	15
Min-Sheng General Hospital	Other income - others	1,363	1,085
Others	"	651	531
Subsidiary	Operating expenses - other expenses	167	884
Subsidiary	Other income and losses - rental income	1,801	1,824
Subsidiary			
Medzoneasia	Other income - others	-	2,126
Mytrex	"	110	110
Others	"	217	61
		<b>\$ 34,180</b>	<b>37,020</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

<b>Category of the related party</b>	<b>Account items</b>	<b>2025.12.31</b>	<b>2024.12.31</b>
Substantial related party			
Pisheng Construction	Prepayments	\$ -	934
Others	"	-	46
Min-Sheng General Hospital	Refundable deposits	400,000	250,000
Others	"	31,815	31,686
Min-Sheng General Hospital	Deposits received	5,856	5,085
Dayuan Min-Sheng Hospital	"	-	902
Others	"	313	3,652
Parent company	Refundable deposits	500	500
Subsidiary	"	84	83
Parent company	Deposits received	589	4,667
Subsidiary	"	103	102
		<b>\$ 439,260</b>	<b>297,657</b>

8. Property transactions

(1) Disposal of property, plant and equipment

The breakdown of the disposal of property, plant and equipment of the Company to related parties are summarized as follows:

	<b>2024</b>	
	<b>Disposal proceeds</b>	<b>Gains or losses on disposal</b>
Substantial related party		
Minsheng Asset Management	<b>\$ 7,429</b>	<b>526</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(2) Disposal of investment properties

The breakdown of the disposal of investment properties by the Company to related parties is as follows:

		<b>2024</b>	
		<b>Disposal proceeds</b>	<b>Gains or losses on disposal</b>
Substantial related party			
Dayuan Min-Sheng Hospital		<b>\$ 293,147</b>	<b>117,283</b>

(3) Acquisition of financial assets

		<b>2025</b>		
<b>Category of the related party</b>	<b>Account items</b>	<b>Number of shares traded</b>	<b>Object of transaction</b>	<b>Acquisition price</b>
Substantial related party - Giant Bonding Scientific	Equity method investments	420	Ordinary share equity of Pregetic	<b>\$ 25,200</b>

(4) Disposal of financial assets

		<b>2025</b>			
<b>Category of the related party</b>	<b>Account items</b>	<b>Number of shares traded</b>	<b>Object of transaction</b>	<b>Disposal proceeds</b>	<b>Gains or losses on disposal</b>
Substantial related party – Chieh pang Technology	Equity method investments	420	Ordinary share equity of Pregetic	<b>\$ 25,200</b>	<b>2,716</b>

9. Endorsement/Guarantee

<b>Category of the related party</b>	<b>2025.12.31</b>	<b>2024.12.31</b>
Substantial related party - Min-Sheng General Hospital	<b>\$ 231,029</b>	<b>229,880</b>

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

(IV) Transactions with key management personnel

Remuneration paid to key management personnel includes:

	<b>2025</b>	<b>2024</b>
Short-term employee benefits	\$ 46,754	37,599
Post-employment benefits	264	1,060
	<b>\$ 47,018</b>	<b>38,659</b>

**VIII. Pledged Assets**

The book values of the assets pledged as collateral by the Company are as follows:

Name of the asset	Pledge object	2025.12.31	2024.12.31
Financial assets measured at amortized cost - non-current	Bank loans	\$ 30,000	30,000
Property, plant and equipment	Bank loans	1,104,117	1,121,256
		<b>\$ 1,134,117</b>	<b>1,151,256</b>

**IX. Material Contingent Liabilities and Unrecognized Contractual Commitments**

Material unrecognized contractual commitments

	2025.12.31	2024.12.31
Purchase of property, plant and equipment	\$ -	10,370
Purchase of intangible assets	10,951	-
Guaranteed notes issued for bank loan contracts	1,981,000	2,485,000
	<b>\$ 1,991,951</b>	<b>2,495,370</b>

**X. Material Losses from Disasters: none.**

**XI. Material Subsequent Events: none.**

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

**XII. Others**

(I) Employee benefits, and depreciation and amortization expenses are summarized by function as follows:

By function Nature of business	2025			2024		
	Belonging to operating costs	Belonging to operating expenses	Total	Belonging to operating costs	Belonging to operating expenses	Total
Employee benefit expenses						
Remuneration expenses	103,056	56,719	159,775	85,247	58,011	143,258
Labor and health insurance expenses	9,392	5,368	14,760	7,236	4,276	11,512
Pension expenses	5,359	2,838	8,197	4,396	2,401	6,797
Remuneration to directors	-	7,057	7,057	-	7,310	7,310
Other employee benefit expenses	4,896	3,550	8,446	3,880	2,960	6,840
depreciation expense	103,279	40,120	143,399	107,176	40,900	148,076
Amortization expenses	4,432	785	5,217	1,829	766	2,595

The additional information on the number of employees and employee benefits for the Company for 2025 and 2024 is as follows:

	<u>2025</u>	<u>2024</u>
Number of employees	<u>193</u>	<u>155</u>
Number of directors who do not concurrently serve as employees	<u>7</u>	<u>7</u>
Average employee benefit expenses	<u>\$ 1,028</u>	<u>1,138</u>
Average employee salary expenses	<u>\$ 859</u>	<u>968</u>
Adjustment to average employee salary expenses	<u>(11.26)%</u>	<u>6.49%</u>
Supervisors' remuneration	<u>\$ -</u>	<u>-</u>

Information on the Company's remuneration policy (including directors, managers and employees) is as follows:

1. The Company has formulated a salary assessment method for employees, which is based on the job category of an employee with consideration of the salary for his/her job in the market. An employee' remuneration includes monthly salaries, as well as operating performance bonuses and earnings distributed from the Company's profits, based on his/her job performance and contribution, and the amount of remuneration shall be submitted to the Remuneration Committee for review and to the Board of Directors for approval. The Company is committed to providing employees with a salary higher than the industry average.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

2. The Company's recruitment of managers and remuneration payment for them are based on talents required for the Company's operation and development and the scope of duties and responsibilities of the managers, and shall be submitted to the Remuneration Committee for review and to the Board of Directors for approval.
3. The Company conducts annual budget review and sets performance goals for the business units, and pays performance bonuses based on the achievement of performance goals.
4. The Company has established standards for the appropriation of directors' and employees' remuneration. According to the Company's Articles of Incorporation, the Company shall appropriate 6% - 10% of its profits as employees' remuneration, and no more than 3% as directors' remuneration. The appropriation and distribution shall be regularly submitted to the Remuneration Committee for review and to the Board of Directors for approval every year. The same procedure applies to the distribution.

**XIII. Items Disclosed in Notes**

(I) Information on major transactions

For 2025, the Company shall disclose the following significant transactions in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers:

1. Lending of funds to others: None.
2. Making of endorsements and guarantees for others:

Unit: NT\$ thousand

No.	Name of the endorser/guarantor	Endorsed/ guaranteed party		Limit of endorsement/guarantee amount for a single enterprise	Maximum endorsement/guarantee balance for the period	Ending endorsement / guarantee balance	Actual drawdown amount	Amount of property pledged for endorsements/guarantees	Ratio of accumulated endorsements/guarantees to net value in the latest financial statements	Maximum amount for endorsements/guarantees	Endorsements/guarantees provided by parent company to subsidiaries	Endorsements/guarantees provided by subsidiaries to parent company	Endorsements/guarantees in China
		Name of company	Relationship										
	ShareHope Medicine Co., Ltd.	Min-Sheng General Hospital	1	1,554,346	231,029	231,029	231,029	-	6.71%	1,721,881	N	N	N

Note 1: The explanation of the number column is as follows:

- (1) Fill in 0 for the issuer.
- (2) The investees are numbered sequentially with Arabic numerals starting from 1 by company type.

Note 2: There are 7 types of relationships between the endorser and the endorsee. Please mark the type:

- (1) Companies with who the Company does business.
- (2) Companies in which the Company directly and indirectly holds more than 50% of the voting shares.
- (3) Companies that directly and indirectly hold more than 50% of the Company's voting shares.
- (4) Companies in which the Company directly and indirectly holds more than 90% of the voting shares.
- (5) Companies among the peers and co-contractors that provide mutual guarantee for the purposes of undertaking projects in accordance with contractual terms.
- (6) Companies that are endorsed/guaranteed by all contributing shareholders in proportion to their shareholdings due to joint investments.
- (7) Peers who provide joint guarantees for the performance of house presales contracts in accordance with the Consumer Protection Act.

Note 3: The limits specified in the Procedures for Endorsement and Guarantee of ShareHope Medicine Co., Ltd. are as follows:

- (1) The endorsement and guarantee amount for a single enterprise shall not exceed 20% of the current net value, and the amount of an endorsement/guarantee provided for a transaction shall not exceed the

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co., Ltd. (Continued)**

total amount of the transaction made by the enterprise with ShareHope Medicine Co., Ltd.

(2) The total amount of endorsements and guarantees provided for others shall not exceed 50% of the current net value.

3. Material securities held at the end of the period (excluding investments in subsidiaries and affiliates, and interests in joint ventures):

Unit: NT\$ thousand

Holder of securities	Type and name of securities	Relationship with securities issuer	Accounting subject	End of period				Remarks
				Contribution amount/number of shares (thousand shares or units)	Carrying amount	Shareholding ratio	Fair value	
The Company	Fund beneficiary certificate Union Money Market Fund	None	Financial assets at fair value through profit or loss - current	771	10,769	-	10,769	
Macro Global Corporation	Franklin Templeton Technology Fund	None	Financial assets at fair value through profit or loss - current	2	2,011	-	2,011	
					12,780		12,780	
The Company	Stock Tsashin Health Business Co., Ltd.	None	Financial assets at fair value through profit or loss - non-current	1,000	23,983	3.70%	23,983	
The Company	Stock ADIMMUNE CORPORATION	None	Financial assets at fair value through profit or loss - non-current	12	227	-	227	
					24,210		24,210	
The Company	Stock BenQ BM Holding Cayman Corporatio	None	Financial assets at fair value through other comprehensive income - current	5,258	87,264	1.69%	87,264	
The Company	Stock Top Taiwan XIV Venture Capital Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	2,000	17,997	0.92%	17,997	
The Company	Stock CDIB Venture Capital Corporation	The Company is a legal representative supervisor of the company	Financial assets at fair value through other comprehensive income - non-current	4,057	55,552	2.86%	55,552	

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

Holder of securities	Type and name of securities	Relationship with securities issuer	Accounting subject	End of period			Remarks	
				Contribution amount/number of shares (thousand shares or units)	Carrying amount	Shareholding ratio		Fair value
The Company	Stock Top Taiwan XI Venture Capital Co., Ltd.	The Company is a legal person director of the company	Financial assets at fair value through other comprehensive income - non-current	3,276	31,606	7.50%	31,606	
The Company	Limited partnership equity Chunghua Development Second Biomedical Venture Capital Limited Partnership	None	Financial assets at fair value through other comprehensive income - non-current	93,242	96,541	3.22%	96,541	
The Company	Stock -AcroViz Inc.	None	Financial assets at fair value through other comprehensive income - non-current	1,820	27,591	8.88%	27,591	
The Company	Stock -UltraE Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	1,176	17,915	6.47%	17,915	
The Company	Stock -Yaosheng Information Technology Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	500	28,571	10.00%	28,571	
Mytrex Health Technologies, Inc.	Stock -Min-Sheng Asset Management Co., Ltd.	The chairperson of the Company is a director of the company	Financial assets at fair value through other comprehensive income - non-current	2,120	19,712	3.37%	19,712	
Mytrex Health Technologies, Inc.	Stock Shangching Technology Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	68	1,590	0.81%	1,590	
Mytrex Health Technologies, Inc.	Stock Intelligent Medical Technology Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	1,760	26,750	9.99%	26,750	
Mytrex Health Technologies, Inc.	Stock Yiho Smart Technology Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	250	8,330	19.53%	8,330	
Mytrex Health Technologies, Inc.	Stock Yichuang Second Venture Capital Co., Ltd.	The Company is a director of the company	Financial assets at fair value through other comprehensive income - non-current	5,000	44,990	2.29%	44,990	
Precision Health Inc.	Stock Yita International Hospital Management Consulting Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	417	4,900	4.20%	4,900	
Macro Global Corporation	Stock Juichuan Data Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	1,250	13,532	10.87%	13,532	
Macro Global Corporation	Stock Kangchien Gene Technology Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	1,304	13,386	14.81%	13,386	
Macro Global Corporation	Limited partnership equity Chunjuang Development Venture Capital Limited Partnership	None	Financial assets at fair value through other comprehensive income - non-current	17,466	21,712	1.75%	21,712	
					430,675		430,675	

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co., Ltd. (Continued)**

4. The amounts from purchase and sale of goods from and to related parties that amount to NT\$100 million or account for more than 20% of the paid-in capital:

Unit: NT\$ thousand

Purchaser (seller)	Name of the counterparty	Relationship	Transaction details				Cases where transactions are made in different conditions from general transactions and the reasons		Notes and accounts receivable (payable)		Remarks
			Purchase (sell)	Amount	Ratio of the amount to total purchases (sales)	Credit period	Unit price	Credit period	Balance	Percentage of total notes and accounts receivable (payable)	
The Company	Min-Sheng General Hospital	Substantial related party	(Sell)	(1,048,806)	(43.86)%	Net 180 days	-		562,578	49.65%	
The Company	Min-Sheng General Hospital	Substantial related party	Service income	(449,072)	(18.78)%	Net 30-180 days	-		244,273	21.56%	
The Company	Min-Sheng General Hospital	Substantial related party	Lease income	(56,468)	(2.36)%	Net 30-180 days	-		5,924	0.52%	
									<u>812,775</u>		
The Company	YES Health Co., Ltd.	Subsidiary	(Sell)	(290,091)	(12.13)%	Net 60 days	-		182,481	16.11%	
YES Health Co., Ltd.	The Company	Parent company	Purchase	290,091	18.43%	Net 60 days	-		(182,481)	(54.16)%	

5. Receivables from related parties amount to NT\$100 million or account for more than 20% of the paid-in capital:

Unit: NT\$ thousand

Payee of the accounts receivable	Name of the counterparty	Relationship	Balance of related party receivables	Turnover rate	Overdue related party receivables		Amount received in subsequent periods	Provision for loss allowances
					Amount	Accounting treatment		
The Company	Min-Sheng General Hospital	Substantial related party	812,775	1.88	-		262,759	-
The Company	YES Health Co., Ltd.	Subsidiary	182,481	2.45	-		23,658	-

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co., Ltd. (Continued)**

(II) Information on reinvestment (excluding investees in mainland China):

Information on the investees of the Company in 2025 is as follows:

Unit: NT\$ thousand/thousand shares

Name of investee	Name of investee	Region	Principal business	Initial investment amount		Shareholding at the end of the period			Profits and losses of the investee for the period	Investment income and losses recognized for the period	Remarks
				End of the period	End of last year	Number of shares	Ratio	Carrying amount			
The Company	Mytrex Health Technologies, Inc.	Taoyuan City	Manufacturing and processing of non-woven fabrics and sales of medical and sanitary materials	310,286	310,286	22,454	61.46%	343,781	(16,600)	(10,203)	
The Company	ShareHope Hong Kong Company	Hong Kong, China	Investment management	44,831	44,831	1,500	100.00%	14,431	(5,646)	(5,646)	
The Company	Chungyuan Medical Management Company	Taoyuan City	Management Consulting Services	11,389	11,389	1,000	100.00%	11,959	291	291	
The Company	Medzoneasia	Taoyuan City	Health management services and hotels	-	338,169	-	-%	-	-	-	Note 2
The Company	Precision Health Inc.	Taoyuan City	Health management services	122,006	122,006	12,601	38.19%	69,427	(23,702)	(9,057)	
The Company	Shengshih Technology Co., Ltd.	Taipei City	Management Consulting Services	1,000	1,000	100	100.00%	625	(64)	(64)	
The Company	Digimed	Taipei City	Information software services	6,000	-	600	60.00%	2,564	417	250	Note 1
The Company	TECHGROUP	New Taipei City	Medical information software services	50,759	-	1	51.00%	34,611	6,546	398	Note 1
The Company	Global Biotech Multimedia Co., Ltd.	Taipei City	Magazine (periodical) publication	10,000	-	500	23.98%	10,223	3,423	861	Note 1
The Company	Shengyu Health Technologies Co., Ltd.	Taoyuan City	Other management consulting services	2,000	-	200	40.00%	-	1	-	Note 1
The Company	HoHoHo Health Life Co., Ltd.	Taipei City	Cosmetics Manufacturing Industry	20,000	-	2,000	20.00%	20,000	-	-	
Medzoneasia	Digimed	Taipei City	Information software services	-	6,000	-	-%	-	-	-	
Medzoneasia	TECHGROUP	New Taipei City	Medical information software services	-	50,759	-	-%	-	-	-	
Medzoneasia	Global Biotech Multimedia Co., Ltd.	Taipei City	Magazine (periodical) publication	-	10,000	-	-%	-	-	-	
Medzoneasia	Shengyu Health Technologies Co., Ltd.	Taoyuan City	Other management consulting services	-	2,000	-	-%	-	-	-	
Mytrex Health Technologies, Inc.	Mytrex USA Co.	California, USA	Health care support services	-	23,516	-	-%	-	(4,587)	(4,102)	
Mytrex Health Technologies, Inc.	Air Long-Term Care Co., Ltd.	Taoyuan City	Management Consulting Services	10,000	10,000	667	22.37%	11,925	4,470	1,000	
Mytrex Health Technologies, Inc.	Mytrex	Taoyuan City	Manufacturing and processing of non-woven fabrics and sales of medical and sanitary materials	447,888	447,888	6,000	100.00%	65,062	5,067	5,034	
Mytrex Health Technologies, Inc.	Sheng Yo Company	Tainan City	Health management services	-	22,381	-	-%	-	(18,093)	(9,388)	Note 5
Mytrex Health Technologies, Inc.	YES Health Co., Ltd.	Taoyuan City	Wholesale and trading of medicines and management consulting for pharmacies	230,000	230,000	6,035	100.00%	211,498	4,559	3,908	
Chungyuan Medical Management Company	Air Long-Term Care Co., Ltd.	Taoyuan City	Management Consulting Services	2,000	2,000	200	6.71%	2,525	4,470	300	
Precision Health Inc.	Hung-Han Company	Taipei City	Health management services	-	128,880	-	-%	-	-	608	Note 3
Precision Health Inc.	CRAFTION INC.	Taipei City	Advertising	-	1,700	-	-%	-	(474)	(711)	Note 7
Precision Health Inc.	Harvard Company	Taipei City	Health management consulting services	-	259,288	-	-%	-	-	(19,360)	Note 3
Precision Health Inc.	Anchun Technology Co., Ltd.	Taipei City	Health management services	-	20,000	-	-%	-	(5,415)	(2,012)	Note 6
Precision Health Inc.	Shang-Jia Health Enterprise Co., Ltd.	Taipei City	Health management services	36,527	36,527	3,390	28.18%	39,610	(969)	(509)	
Precision Health Inc.	Macro Global Corporation	Taichung City	Wholesale and trading of medicines	74,970	-	6,460	100.00%	79,999	5,052	532	Note 4
Hung-Han Company	Macro Global Corporation	Taichung City	Wholesale and trading of medicines	-	74,970	-	-%	-	5,052	4,191	Note 4
Macro Global Corporation	Anchun Company	Taipei City	Health management services	20,000	-	2,000	40.00%	12,907	(5,415)	(154)	Note 6
YES Health Co., Ltd.	Digimed	Taipei City	Information software services	2,000	2,000	200	20.00%	854	417	83	

## Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co., Ltd. (Continued)

Note 1: In response to the reorganization of the Group, the investee, Medzoneasia, was merged by the parent company in January 2025. Therefore, the investee was directly held by the Company.

Note 2: The Company and Medzoneasia conducted a short-form merger in January 2025. After the merger, the Company is the surviving company and Medzoneasia is discontinued.

Note 3: Hung-Han, Harvard Health, and Pregetic Medical conducted a short-form merger in July 2025. After the merger, Pregetic is the surviving company and Hung-Han and Harvard Health were dissolved.

Note 4: In response to the reorganization of the Group, Hung-Han was merged by Precision Health Inc., the parent company, in July 2025. Therefore, the investee was directly held by Precision Health Inc.

Note 5: Sheng Yo Rehabilitative Technologies, Inc. resolved at the shareholders' meeting on August 12, 2025 to proceed with dissolution and liquidation.

Note 6: Precision Health Inc. disposed of all equity interests in An-Chun Company to Macro Global Corporation, and the share transfer date was November 27, 2025.

Note 7: Precision Health Inc. disposed of all equity interests in Employee Community Company, and the share transfer date was May 13, 2025.

### (III) Information on investments in mainland China:

#### 1. Information on reinvestments in mainland China:

Unit: NT\$/US\$ thousand

Name of investee company in Mainland China	Principal business	Paid-in capital	Investment method (Note 1)	Accumulated investment amount remitted from Taiwan at the beginning of the period	Investment amount remitted outward or inward in the period		Accumulated investment amount remitted from Taiwan at the end of the period	Profits and losses of the investee for the period	Shareholding ratio of the Company's direct or indirect investment	Investment income and losses recognized for the period (Note 2)	Book value of investment at the end of the period	Investment income repatriated as of the end of the period
					Outward remittance	Inward remittance						
Minsheng (Tianjin) Investment Management Co., Ltd.	Investment management	11,885	(II)	11,885	-	-	11,885	(2,046)	100.00%	(2,046)	3	-
Min-Sheng Asia-Pacific (Beijing) Enterprise Management Co., Ltd.	Hospital management consulting services	5,124	(I)	5,124	-	-	5,124	(1,261)	100.00%	(1,261)	5,144	-

Note 1: Investment methods can be classified into the following three types:

(I) Directly invest in mainland China.

(II) Reinvest in mainland companies through third regions.

(III) Other methods.

Note 2: Financial statements audited by a certified public accountant of the parent company in Taiwan.

**Notes to the Parent Company Only Financial Statements of ShareHope Medicine Co.,  
Ltd. (Continued)**

2. Limits for reinvestment in mainland China:

Unit: NT\$ thousand

<b>Accumulated investment amount remitted from Taiwan to mainland China as of the end of the period</b>	<b>Investment amount approved by the Investment Commission of the Ministry of Economic Affairs</b>	<b>Mainland China investment limit stipulated by the Investment Commission of the Ministry of Economic Affairs (Note)</b>
17,009	17,009	2,066,257

Note: 60% of the net value.

3. Information on major transactions: none.

**XIV. Department Information**

Please refer to the 2025 consolidated financial statements.

**ShareHope Medicine Co., Ltd.**  
**Schedule of Cash and Cash Equivalents**  
**December 31, 2025**

**Unit: NT\$ thousand**

<b>Item</b>	<b>Summary</b>	<b>Amount</b>
Cash on hand and working capital	Cash and working capital	\$ 4,076
Bank deposits	Demand deposits	892,459
	Foreign currency demand deposits (Note 1)	62
Cash equivalents	Repurchase bonds (Note 2)	51,549
		<b><u>\$ 948,146</u></b>

Note 1:

<b>Amount in original currency (NT\$)</b>	<b>Exchange rate</b>
USD1,519.69	31.43
CNY3,270.76	4.496

Note 2:

<b>Amount in original currency (NT\$ thousand)</b>	<b>Maturity date</b>	<b>Interest rate</b>
NTD51,549	2026.2.11	0.90%

**ShareHope Medicine Co., Ltd.**  
**Schedule of Notes and Accounts Receivable**  
**and Finance Lease Receivables**

**December 31, 2025**

**Unit: NT\$ thousand**

<b>Item</b>	<b>Customer name</b>	<b>Amount</b>
Notes receivable	New Kunming Hospital	\$ 689
	Kangchihyo Pharmacy	56
	Lehua Kangchihyo Pharmacy	42
		<b>\$ 787</b>
Accounts receivable	Weikung	\$ 8,438
	Yungkeng	30,094
	Others (less than 5% of the balance of this item)	22,144
		<b>\$ 60,676</b>
Accounts receivable - related parties	Min-Sheng General Hospital	\$ 811,785
	Yes Chain Pharmacy	182,481
	Others (less than 5% of the balance of this item)	60,486
Loss allowances		(1)
	Net accounts receivable - related parties	<b>\$ 1,054,751</b>
Finance lease receivables	Horei	\$ 6,182
	Others (less than 5% of the balance of this item)	71
		<b>\$ 6,253</b>
Finance lease receivables - related parties	Precision Health Inc.	\$ 455
	Zhiyi Clinic	979
	Min-Sheng General Hospital	990
	Dayuan Min-Sheng Hospital	2,348
	Longtan Min-Sheng Hospital	1,009
		<b>\$ 5,781</b>
Long-term finance lease receivables	Aikossu	<b>\$ 567</b>
Long-term finance lease receivables - related parties	Precision Health Inc.	\$ 673
	Dayuan Min-Sheng Hospital	3,062
	Longtan Min-Sheng Hospital	517
		<b>\$ 4,252</b>

ShareHope Medicine Co., Ltd.

Schedule of Financial Assets at Fair Value through Profit or Loss - Current  
and Non-current

December 31, 2025

Unit: NT\$ thousand/thousand shares

Name of financial instrument	Summary	Shares or units	Face value	Total amount	Acquisition cost	Fair value	
						Unit price	Total amount
Financial assets at fair value through profit or loss - current							
Fund beneficiary certificate	Union Money Market Fund	771	\$ 10,000	<u>10,000</u>	10,000	13.97	<u>10,769</u>
Financial assets at fair value through profit or loss - non-current							
Non-TWSE/TPEX listed stocks	Tsaishin Health Business Co., Ltd.	1,000	-	-	15,000	23.98	23,983
Non-TWSE/TPEX listed stocks	ADIMMUNE CORPORATION	12	-	-	228	18.95	227
				<u>\$ 10,000</u>			<u>24,210</u>

**ShareHope Medicine Co., Ltd.**

**Schedule of Financial Assets at Fair Value through Other Comprehensive Income -  
current and non-current**

**January 1 to December 31, 2025**

**Unit: NT\$ thousand/thousand shares**

<u>Name</u>	<u>Beginning balance</u>		<u>Shares increase in the current period</u>	<u>Decrease during the period</u>		<u>Fair value of valuation gains and losses</u>	<u>Ending balance</u>		<u>Guarantee or pledge</u>	
	<u>Number of shares</u>	<u>Amount</u>		<u>Number of shares</u>	<u>Amount</u>		<u>Number of shares (thousand shares)</u>	<u>Amount</u>		
Chunghua Development Biomedical Venture Capital Co., Ltd.	4,311	\$ 27,740	-	-	254	2,535(Note 2)	30,347	4,057	55,552	None
Yiting Biotech Venture Capital Co., Ltd.	4,095	42,629	-	-	819	8,190 (Note 2)	(2,833)	3,276	31,606	"
BenQ BM Holding Cayman Corporation	5,258	345,774	-	-	-	-	(258,510)	5,258	87,264	"
Chunghua Development Second Biomedical Venture Capital Limited Partnership	-	98,744	-	9,614	-	2,718 (Note 3)	(9,099)	-	96,541	"
Yichuang Second Venture Capital Co., Ltd.	2,000	16,925	-	-	-	-	1,072	2,000	17,997	"
AcroViz Inc.	1,820	25,498	-	-	-	-	2,093	1,820	27,591	"
UltraE Co., Ltd.	1,176	23,440	-	-	-	-	(5,525)	1,176	17,915	"
Yaosheng Information Technology Co., Ltd.	-	-	500	27,230(Note 1)	-	-	1,341	500	28,571	"
		<b><u>\$ 580,750</u></b>		<b><u>36,844</u></b>		<b><u>13,443</u></b>	<b><u>(241,114)</u></b>		<b><u>363,037</u></b>	

Note 1: As a result of the short-form merger with the subsidiary Medzoneasia Co., Ltd., the Company holds the equity interests in Yaosheng Information Technology Co., Ltd. originally held by Medzoneasia Co., Ltd.

Note 2: Represents capital returned from capital reduction of the investee.

Note 3: Represents return of capital contributions from the investee.

**ShareHope Medicine Co., Ltd.**  
**Schedule of Changes in Equity Method Investments**  
**January 1 to December 31, 2025**

**Unit: NT\$ thousand/thousand shares**

Item	Beginning balance			Increase during the period		Decrease during the period (Note 1)		Share of profits and losses recognized using the equity method	Unrealized gains or losses on financial assets at fair value through other comprehensive income	Cumulative translation adjustment	Others (Note 2)	Ending balance				
	Number of shares	Shareholding ratio	Amount	Number of shares	Amount	Number of shares	Amount					Number of shares	Shareholding ratio	Amount	Guarantee or equity value	Pledge
Chungyuan Medical Management Co., Ltd.	1,000	100.00%	\$ 11,800	-	-	-	(132)	291	-	-	-	1,000	100.00%	11,959	11,959	None
Mytrex Health Co., Ltd.	22,454	61.46%	353,160	-	-	-	-	(10,203)	1,259	(698)	263	22,454	61.46%	343,781	343,781	"
Medzoneasia Co., Ltd. (hereinafter referred to as Medzoneasia)	17,254	100.00%	69,811	-	-	(17,254)	(69,811)	-	-	-	-	-	-	-	-	"
ShareHope Medicine (HongKong) Co., Ltd.	1,500	100.00%	20,208	-	-	-	-	(5,646)	-	(131)	-	1,500	100.00%	14,431	14,431	"
Minsheng Asia-Pacific (Beijing) Enterprise Management Co., Ltd.	-	100.00%	6,426	-	-	-	-	(1,261)	-	(21)	-	-	100.00%	5,144	5,144	"
Digimed Co., Ltd. (hereinafter referred to as Digimed)	-	-	-	600	2,314	-	-	250	-	-	-	600	60.00	2,564	2,564	"
Precision Health Inc.	12,601	38.19%	80,614	-	-	-	-	(9,057)	(3,157)	-	1,027	12,601	38.19%	69,427	69,427	"
Shengshih Technology Co., Ltd.	100	100.00%	689	-	-	-	-	(64)	-	-	-	100	100.00%	625	625	"
TECHGROUP Integrate Design Co., Ltd.	-	-	-	1	37,346	-	(3,133)	398	-	-	-	1	51.00%	34,611	34,611	"
Global Biotech Multimedia Co., Ltd.	-	-	-	500	9,362	-	-	861	-	-	-	500	23.98%	10,223	10,223	"
HoHoHo Health Life Co., Ltd.	-	-	-	2,000	20,000	-	-	-	-	-	-	2,000	20.00%	20,000	20,000	"
Shengyu Health Technologies Co., Ltd.	-	-	-	200	-	-	-	-	-	-	-	200	40.00%	-	-	"
			<u>\$ 542,708</u>		<u>69,022</u>		<u>(73,076)</u>	<u>(24,431)</u>	<u>(1,898)</u>	<u>(850)</u>	<u>1,290</u>			<u>512,765</u>		

(Note 1) Represents cash dividends received from subsidiaries amounting to NT\$3,265 thousand, and a decrease arising from the short-form merger of subsidiaries amounting to NT\$69,811 thousand.

(Note 2) Recognition of NT\$551 thousand due to remeasurement of subsidiaries' defined benefit plans, and NT\$739 thousand due to changes in ownership interests in the subsidiaries.

**ShareHope Medicine Co., Ltd.**  
**Schedule of Notes and Accounts Payable**  
**December 31, 2025**

**Unit: NT\$ thousand**

<b>Item</b>	<b>Summary</b>	<b>Amount</b>
Notes payable	PerkinElmer	<b>\$ 1,214</b>
Accounts payable	Yuli	\$ 86,007
	DKSH	65,110
	Chunyu	26,530
	Others (those less than 5% of the balance of this item)	338,093
		<b>\$ 515,740</b>
Accounts payable - related parties)	Macro Global Corporation	\$ 538
	Pisheng Construction	306
	Hsinchu Science Park Clinic	162
	Others (those less than 5% of the balance of this item)	11
		<b>\$ 1,017</b>

**ShareHope Medicine Co., Ltd.**  
**Schedule of Operating Costs**  
**January 1 to December 31, 2025**

**Unit: NT\$ thousand**

<u>Summary</u>	<u>Summary</u>	<u>Amount</u>
Sales costs	Beginning inventory	\$ 32,907
	Add: net purchases during the period	1,604,369
	Logistics service fee	6,614
	Less: transferred for own use	(1,198)
	Ending inventory	(27,241)
		<u>1,615,451</u>
Lease costs	Depreciation	<u>67,207</u>
Service costs	Consumables inspection	115,984
	Salaries and bonuses	89,112
	Rent	27,404
	Depreciation	17,748
	Others (those less than 5% of the balance of this item)	53,938
		<u>304,186</u>
Cost of catering and accommodation services	Food ingredients	5,733
	Salaries and bonuses	13,944
	Utilities expenses	10,113
	Repair and maintenance expenses	4,531
	Depreciation	18,324
	Others (those less than 5% of the balance of this item)	13,887
		<u>66,532</u>
Operating costs		<u><b>\$ 2,053,376</b></u>

**ShareHope Medicine Co., Ltd.**  
**Schedule of Operating Expenses**  
**January 1 to December 31, 2025**

**Unit: NT\$ thousand**

<b>Item</b>	<b>Marketing expenses</b>	<b>Administrative expenses</b>	<b>Total</b>
Salaries and bonuses	\$ 10,007	46,712	56,719
Pensions	777	2,061	2,838
Rental expenses	954	3,754	4,708
Service expenses	523	11,706	12,229
Other expenses	1,108	15,210	16,318
Employees' and directors' remuneration	-	13,230	13,230
Depreciation	37	40,083	40,120
Others (those less than 5% of the balance of this item)	3,672	20,917	24,589
	<b>\$ 17,078</b>	<b>153,673</b>	<b>170,751</b>